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Abstract 
 
Cranberry, Vaccinium oxycoccos, and lingonberry, Vaccinium vitis-idaea, have long been known to provide many 
health benefits as a source of nutrition. Similar to other berries, these traditional herbs contain flavonoids and 
vitamins, but also have a special benefit to prevent urinary tract infection (UTI). Previous studies have shown that 
A-type proanthocyanins (PAC) of cranberries may influence the adhesion of bacteria causing urinary tract infection. 
UTI pathogens originate from the gut and earlier studies have shown that there is a connection between urinary tract 
and gut microbiome UTI causing pathogens. However, the cranberry mechanism of action on the gut and urinary 
tract microbiome is not yet elucidated.  
This study aimed to investigate the Cranberry-Lingonberry juice (CLJ) effect on the gut and urinary tract 
bacterial communities. The hypothesis assumed that the metabolism of proanthocyanidins in the gut alters bacterial 
communities and reduces the amount of E. coli and possibly other proteobacteria in the urine. The research was 
done by examining urine and fecal samples from children with urinary tract infection for three (urine) to twelve 
(fecal samples) months. The samples were collected by Oulu University Hospital Child Health and Maternity Clinic 
from 77 patients who drank CLJ or flavonoid-free control juice in randomized trial. Total of 206 samples, including 
40 urine and 166 fecal samples, were collected for study. 
DNA was extracted from samples using two different DNA extraction protocols of QIAGEN, USA and 
quantified using Nanodrop spectrophotometer. The bacterial 16S rRNA was amplified by using Polymerase chain 
reaction (PCR), which also attached unique barcodes for each sample. Agarose gel electrophoresis was used to 
ensure amplification of PCR. All amplified PCR products were prepared for sequencing by Ion Torrent next 
generation sequencing.  
The QIIME 2 next-generation microbiome bioinformatics platform was used to analyze the sequence data and 
metadata information. Greengenes 16S rRNA, Silva gene databases and Human oral microbiome database (HOMD) 
were used as alignment reference databases. Metadata information about sample material and collection time was 
used for grouping. The alpha - and beta diversity, as well as differential abundances between treatments, were 
analyzed using QIIME 2 platform and R-statistical program. Compliance data was used to limit the data to patients 
who used more than 80 % probability of CLJ or control juice in the second round of statistical analysis. 
Altogether 183 samples were amplified, of which 150 was fecal and 40 urine, for downstream analysis. From 
the samples, 18 different phyla and 511 genera were identified, most of them even at species level. 
Statistical analysis showed no significant differences in alpha- or beta diversity between CLJ and controls in 
any groups. Different abundances between treatment groups were found, but in the end none of them were 
statistically significant. By using HOMD-database, E. coli and other UTI-related species were identified from 
compliance 80 % limited data. Statistical analyses showed a significant decrease of these bacteria in the urinary 
tract and gut microbiomes of CLJ group patients. In the future, chemical studies about microbial metabolism 
products could be done from the samples to get a more specific view about CLJ treatment effect on gut and microbial 
communities, and cranberry juice polyphenols effect on the body.  
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Abbreviations 
 
AC-PAC  A-type cranberries proanthocyanidins 
ASV   Amplicon sequence variant 
BH-FDR  Benjamini-Hochberg false discovery rate 
CLJ   Cranberry-Lingonberry juice 
CLR  Centered log ratio 
cp  chloroplast 
cpDNA  chloroplast DNA 
control  flavonoid-free control juice 
DNA  Deoxyribonucleic acid  
EDTA  Ethylenediaminetetraacetic acid 
fw  fresh weight 
HOMD  Human Oral Microbiome Database 
ISP  ion sphere particle 
NGS  Next-Generation sequencing 
OTU  Operational Taxonomic Unit  
PAC  Proanthocyanidins  
PC  Principal component 
PCR  Polymerase chain reaction 
PERMANOVA Permutational multivariate analysis of variance 
QIIME2  Quantitative Insights Into Microbial Ecology 2 
rRNA  Ribosomal ribonucleic acid 
St.  The DNA molecular weight standard 
TBE  Tris base, boric acid and EDTA 
UTI  Urinary tract infection 
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1. Literature review 
1.1. Urinary tract infection 
 
Urinary tract infection (UTI) is a common term for all infections in any part of the urinary tract. It's 
one of the most common and studied infections in human. UTI symptoms are painful urination, pelvic 
pain and traces blood in the urine. Typically, women have greater risk of developing UTI. The urinary 
tract can be divided into upper region, containing kidneys and ureters, and lower tract, containing 
bladder and urethra. Infection can be caused by various species of bacteria or fungi that colonize 
urinary tract, however, the gram-negative bacteria Escherichia coli is the most common pathogen 
(Imirzalioglu et al, 2008).  
UTI has been quite thoroughly studied with consistent results. For a long time, it has been a 
common belief that healthy urinary tract is sterile from bacteria. Recently this old-time belief has 
turned upside-down as studies have found natural and beneficial colonization of the urinary tract. 16S 
sequencing technique from healthy women's urine showed that it contains a rich microbial flora. A 
study was done with 65 patients (41 suffer overactive bladder) urine samples contained members of 
the genera Lactobacillus, Corynebacterium, Streptococcus, Actinomyces and Staphylococcus (Hilt et 
al., 2014).  
The study has showed that the UTI caused by E. coli correlated with gender and was clearly more 
common in women (Behzadi et al., 2010).  E. coli and Klebsiella pneumoniae are the most common 
UTI causing bacteria in children under 5 years. The study included 153 patients, of whom 67 were 
girls (Garout et al., 2015). 
Overall only 5-25 % of UTI is caused by another organism than E. coli and K. pneumoniae, mainly 
gram-positive bacteria such as Staphylococcus saprophyticus, Enterococcus faecalis, and 
Streptococcus agalactiae. Typically, the infection is treated with antibiotics, but studies have also 
shown that antibiotic resistance develops against UTI-causing bacteria. This has pushed studies to 
find alternative medications (Imirzalioglu et al, 2008).   
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1.2. Cranberry and lingonberry for prevention of urinary tract infection 
 
Cranberry has long been old folk medicine for urinary tract infection. There have been different 
theories about mechanism of action. Cranberry makes urine more acidic, and typically this is believed 
to be reason. Acidic conditions are less favorable for UTI causing pathogens like E. coli.  
First study to show cranberries affecting urine acidity was made in 1914 by Blatherwick, but 
observations about cranberries benzoic acid affect to decrease urine pH was made by German 
physicians in 1880s. Cranberries benzoic acid is combined with glycine in the body and is excreted 
in urine as hippuric acid (Blatterwick, 1919). After that studies on cranberry effect on decreasing 
urine pH have been done regularly, but none has showed that cranberries benzoic acid could decrease 
urine acidity enough to make it bacteriostatic. Even four liter of cranberry juice per day is not enough 
to produce needed amount of hippuric acid (Raz et al., 2004). 
Nowadays researchers have a different theory. Cranberry phytochemical compounds have been 
noticed to affect adhesion of pathogenic bacteria in urinary tract. One theory suggests that compounds 
make urinary cell walls more slippery for bacteria to stick (Gupta K et al., 2007; Lavigne et al., 2008) 
and other theory thinks that the compounds change bacterial mechanisms of attaching to urinary tract. 
E. coli has hairlike fimbria on their surface which bacteria use to adhere the receptors on uroepithelial 
cells (Liu Y et al., 2008). When adhering to receptors, bacterial fimbriae produce two adhesions, one 
mannose sensitive and one mannose resistant. (Raz et al., 2004). 
Cranberries antiadherent properties were first studied by Sobota et al. in 1984. They found out 
that cranberry juice reduced E. coli from clinical isolates from patients with UTI (Sobota et al. 1984). 
After that more studies by different approaches have been done to confirm the hypothesis. In 1989 
two phytochemical components of cranberries, fructose and proanthocyanidins (PAC), were showed 
to produce antiadherent properties against E. coli adhesion.  Fructose has been shown to inhibit the 
mannose sensitive, type I fimbriae, adhesion - and PACs mannose-resistant, p-fimbriae, adhesions 
(Zafriri et al., 1989). From those, fructose can be found from many food sources and its role seems 
more minimal. PACs are more special and are found in significant numbers in genus Vaccinium 
species (Raz et al., 2004).  
Many clinical studies have subsequently been conducted in patients with different background to 
confirm this hypothesis. Typically, in clinical trials, cranberry effect to prevent urinary tract 
symptoms is studied in adult women, elderly or pediatric patients. Studies suggest that PACs prevent 
UTI in two ways. Compounds strictly prevent E. coli adhesion to uroepithelial cells. PACs adhere to 
E. coli preventing them from adhering cellular receptors. This makes room for more beneficial 
bacteria to colonize urinary tract microbiome (Raz et al., 2004). 
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Cranberry is also shown to affect other UTI causing pathogens. Earlier in vitro studies have shown 
that cranberry juice extract could inhibit biofilm formation and enzymatic activities of E. faecelis 
strains isolated from urine (Wojnicz, 2016). Similar in vitro studies have also been done for other 
UTI causing pathogens with positive results. Case studies have also been reported for decades and 
there is strong evidence on the beneficial effects of cranberries in treating UTI. PACs have also shown 
to be effective in cases where UTI is caused by antibiotic resistant uropathogenic bacteria (Howell et 
al., 2002). 
Mixed Cranberry-Lingonberry juice (CLJ) has been shown to beneficially affect patients suffering 
from UTI. The juice reduces E. coli biofilm formation and virulence. However, there is little evidence 
of the detailed mechanism or effect of the juice. The juice effect was studied in twenty healthy patients 
who drank juice for two weeks. Virulence gene expression levels between controls and patients were 
analyzed by qPCR, but no significant changes were found, indicating that there must be other 
mechanisms in place (Tapiainen et al., 2012). 
A-type proanthocyanins (PAC) of cranberries can inhibit invasion of extra-intestinal pathogenic 
E. coli in gut epithelial cells in-vitro. The concentration of > 36 µg PAC/ml reduced E. coli invasion 
significantly by cross-linking surface virulence factors. The mechanism was identified by scanning 
electron microscopy. E. coli is typically connected to UTI (Polewski, 2016). Effects of probiotics and 
cross-effect were also studied in the same research, and results showed that synergy between 
bioactive PACs and probiotics produced the best results. PACs worked with Lactobacillus probiotics, 
meaning that PACs affect only E. coli adhesion in this case. These results suggest that combinatory 
medication would be also suitable to treat UTI (Polewski, 2016).  
Other studies also suggest that the best results of UTI treatment would be reached with a 
combination of probiotics selected from common vaginal inhabitants and A-type PACs from 
cranberry juice. For example, Lactobacillus spp. dominate the vaginal cavity microbiome of healthy 
women and could colonize the free space gained from pathogenic E. coli communities due to PAC 
growth inhibition. A-type PACs also reduce fungal Candida albicans adhesion properties (Polewski, 
2016; Rauf et al., 2019). 
Studies have shown that gut microbiome might have a connection with UTI. Typically, UTI is 
caused by microbe originated from gut. Paalanne et al. (2018) showed that there were differences in 
gut microbiome at genus and family levels between healthy children and children with UTI. Less is 
still known about berry polyphenol mechanisms on gut - and urinary tract microbiomes. However, as 
is shown, every study offers a new piece in a puzzle, and maybe someday the puzzle will be 
completed.  
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1.3. Cranberry and lingonberry  
 
Cranberry (Vaccinium ocycoccos) and lingonberry (Vaccinium vitis-idaea) are members of the 
Ericaceae family, which contains other familiar berries like blueberry, bilberry, and huckleberry. 
Most of them are well studied and contain bioactive compounds that are good for health. Studies 
about cranberry health effects are known for several decades in the past. Cranberry is not just one 
species; cranberries are a group of dwarf shrubs in the genus Vaccinium. Colloquially cranberry has 
been used to describe all group members. Lingonberry is also member of the same genus Vaccinium 
and provides mostly similar potential health benefits (Häkkinen et al., 2019). Overall all genera 
provide health effects, being full of vitamins and flavonoids, but still have some levels of differences 
(Baoru et al., 2015).  
Cranberries have a wide phytochemical profile containing approximately 8000-10000 detected 
phytochemicals, of which many are a necessary part of the diet. For example, all cranberries are rich 
in ascorbic acid known as Vitamin C, which is also an antioxidant and an essential nutrient as part of 
the daily diet (Brown et al., 2011). Cranberry bioactive compounds have been studied in European 
cranberry, Vaccinium oxycoccos, and American cranberry, V. macrocarpon. Cranberries also contain 
phenolic acids, catechins and triterpenoids, of which some have biological effects, e.g. in relieving 
chronic diseases (Jurikova et al., 2018). For example, ursolic acid, a phenolic triterpenoid from V. 
oxycoccos, is protective against oxidative damage and lipid oxidation (Ramachandran et al., 2008). 
Anthocyanins, proanthocyanins and flavonols form the majority of cranberry flavonoids, and all are 
associated with human health benefits (Panche et al., 2016). 
Lingonberry, Vaccinium vitis-idaea, contains also necessary parts of diet as vitamins, phenolics 
and omega-3-fatty acids. Mostly it contains same phenolics which are associated with human health 
benefits as cranberries, but those has concentration differences (Heinonen, 2017). 
Both berries are acidic, because they contain citric and malic acid like many other berries. 
Lingonberry and cranberry contain also benzoic acid, which is untypical in other berries (Viljakainen, 
2003). These compounds are components of tannins and make berry juice taste sour.  
 
1.4. Flavonoids 
 
The most important group of bioactive compounds in genus Vaccinium is flavonoids. They are a 
group of secondary plant metabolites that help the plant to survive, grow and reproduce. All 
flavonoids in plants are biosynthesized via the phenylpropanoid metabolic pathway. The pathway can 
use the amino acid phenylalanine or tyrosine as input substrate and produce a wide range of different 
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compounds after many steps that divide pathway to “subset pathways” often named after end products 
with specifying a name. When flavonoids are produced, phenylalanine is pathways input substrate 
(Ververidis et al., 2007). 
Every compound has a specific role in the plant and can act e.g. as antioxidants, antimicrobials, 
and photoreceptors or insect repellant. Bioactive compounds ratio is not stable during flowering and 
fruit ripening in cranberries. Berry maturation has been shown to affect anthocyanin - and 
proanthocyanin (PACs) concentrations in V. macrocarpon. PAC levels are high at the beginning of 
flowering but decrease until late fruit maturation when levels start to increase. Anthocyanin level 
increases during maturation and only flavonol levels stay seemingly constant all the time 
(Vvedenskaya & Vorsa, 2004). Flavonoid concentration between V. oxycoccos and V. macrocarpon 
also differs. V. oxycoccos has the highest concentration of anthocyanins, and PACs are most abundant 
in V. macrocarpon (Povilaityte et al., 1998). Also, both species differ by phenolic compound 
concentrations in individual plants. For example, environmental factors have a significant influence 
on the phytochemical profile of the plant. Climate, cultivating style and area is just a couple of factors 
that have shown to affect individual berry phytochemical profile (Jurikova et al., 2018).  
Flavonoids contain a variety of different compounds with different effects but have a similar 
general structure; the 15-carbon skeleton contains two phenyl rings and one heterocyclic ring. There 
are three main classes; bioflavonoids, isoflavonoids and neoflavonoids, or they can be divided into 
several subgroups according to chemical structure. From the human perspective, the most significant 
groups are anthocyanidins, anthoxantheins (flavones and flavonol), flavanones, flavanols and 
isoflavones (Panche et al., 2016).  
For humans, flavonoids are part of the polyphenol class of phytonutrients containing over 6000 
identified biochemical compounds. Many flavonoids can act as antiviral, -allergenic and -
inflammatory biocompounds. Flavonoids may also function as antioxidants and prevent damage to 
cells caused by free radicals and even the formation of cancer (Panche et al., 2016).  
The flavonoid profile of cranberries has been studied and compared with other berries. A profile 
consists of anthocyanidins, flavan-3-ols and flavonol aglycons. Flavan-3-ols are derivatives of 
flavans. The group consist, members that have a common structural skeleton, 2-phenyl-3,4-dihydro-
2H-chromen-3-ol, e.g. catechin and proanthocyanin include it (Pappas et al., 2009).  
Cranberries and lingonberry, V. vitis-idae, flavonols, quercetin, kaempferol and myricetin have 
antioxidative and other healthy properties, and are typical for other berries also. A study done by 
Ehala et al. (2005) shows that quercetin, which also has antihistamine properties, was the most 
common flavonoid in studied berries. Highest level of 1.2 mg/100 g fresh weight (fw) was found in 
bilberry, V. myrtillus. European cranberry, V. oxycoccos, has over half less (0.52 mg/100 mg fw). 
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Another study done for 25 berries by Häkkinen et al. (1998) has shown also that quercetin is the 
most common flavonol, but concentration levels were much higher. According to this study, 
lingonberry, V. vitis-idae get second place with content 7.4-14.6mg/100g fw and V. oxycoccos gets 
the third place with a level range between 8.3-12.1 mg/100 g fw. The same study showed that 
myricetin, also a potent antioxidant, was common in all berries, with concentrations ranging from 1.4 
to 14.2 mg/100 g fw. Kaempferol wasn’t detected from cranberry and lingonberry. Differences 
between studies might be related to processing procedures. For example, drying conditions have been 
showed to influence flavonoid content in fruits of European cranberry (Adamczak et al., 2009). 
Anthocyanins are especially known for their health benefits. Those have anti-tumour, anti-ulcer, 
antioxidant and anti-inflammatory properties. Due to anthocyanin-related nutritional value, 
anthocyanin content has been studied from berries. Brown et al. (2011) studied it in cranberry juice 
produced from European and American cranberries. The content varied a lot between juice samples, 
and in general, juice produced from American cranberry, V. macrocarpon, seemed to contain more 
anthocyanins. Still, none of the cranberry juice samples was even close in anthocyanin content 
compared to bilberry juice. Bilberry is commonly known for its high anthocyanin levels (Brown, 
2011; Forney et al., 2014). Brown et al. (2011) also showed that cranberry anthocyanin levels do not 
correlate with antioxidative properties. Therefore, other flavonoids, or their cross-effects, seem to be 
more important for antioxidative effect in cranberries. 
Even though both cranberry and lingonberry contain much less anthocyanins than bilberry, 
Vaccinium myrtillus, studies have shown that they consist a variety of other phytochemicals that have 
health potential (Kylli et al., 2011; Jurikova et al., 2018). Anthocyanins are also predominant for 
cranberry, but for lingonberry, V. Vitis-idea, flavonols and procyanidins predominate. Comparing to 
bilberry, extract of lingonberry fruits contains higher total amount of phenolic compounds and 
flavonoids (Dróżdż et al., 2017). Both cranberry and lingonberry contain relatively huge amounts of 
proanthocyanidins which comprise 63-71 % of berry total phenolic compounds (Kylli et al., 2011). 
 
1.5. Proanthocyanidins 
 
Most interesting polyphenol class, according to urinary tract infection (UTI) related studies, is 
proanthocyanidins (PAC) that contains three groups: dimers and trimers, oligomers, and polymers. 
Cranberries and lingonberry contain all of these. The anti-inflammatory, antibacterial and antiviral 
properties of the berries are a result of these compounds (Česonienė et al., 2015).  
The polyphenol structure of PACs consists of repeating units of catechin or epicatechin monomer, 
which is used for grouping. PACs are also called as condensed tannins, and chemically oligomeric 
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flavonoids, meaning that they contain few repeating units. The dimers contain two repeating units, 
trimers three and tetramers four. Tannins are a name for a group of polyphenolic biomolecules that 
bind and precipitate various organic compounds, mostly proteins. The chemical structure of tannins 
contains polymeric building blocks. In principle, polymers can contain an infinite number of 
repeating units in “loosely form”, so they are considerably lighter in molecular weight compared to 
PACs (Česonienė et al., 2015).  
Shorter PACs, built from catechin and epicatechin, are non-hydrolyzable tannins, meaning that 
they are formed by the condensation of flavans and they do not contain sugar residues. Hydrolyzable 
tannins have carbohydrate at the centre of the 
molecule — those form gallic or ellagic acids when 
heated. Hydrolyzable tannins have shown to have 
antibacterial properties against Helicobacter pylori. 
Polyphenols found from red wine and green tea are 
shown to inhibit the VacA toxin, which is a major 
virulence factor of Helicobacter pylori. Tannin 
effects against cancer have been studied in the 2000’s 
(Funatogawa, 2004). Tannins may somehow improve 
protection against colon cancer by decreasing 
carcinogen-induced aberrant crypt formation, colonic 
cell proliferation and oxidative DNA damage. Both tannin groups are typically found in tea, coffee 
and wine (Beecher, 2004). 
Among short PACs, A- and B-type proanthocyanidins that differ by structure, have a different 
effect on human microbiome. The A-type dimers and trimers are typical in European cranberry, V. 
oxycoccos, whose proanthocyanins levels are relatively high up to 63-71 % (1.5-2.0 mg/100g) of total 
amount of phenolic compounds (Määttä-Riihinen et al., 2005). A-type cranberries PACs (AC-PACs) 
are shown to affect urinary tract microbiomes pathogenic type bacterias adhesion to tissue walls 
(Kline & Lewis, 2016). In vitro studies has shown that polymeric PACs extracts of lingonberry and 
cranberry were antimicrobial against Staphylococcus aureus. Polymeric and oligomeric PACs of 
cranberry and oligomeric PACs of lingonberry affect E. coli adhesion (Kylli et al., 2011). 
 
  
Figure 1 Proanthocyanin (National Center for 
Biotechnology Information. PubChem Database. 
Proanthocyanidin, CID=108065, 
https://pubchem.ncbi.nlm.nih.gov/compound/Proanth
ocyanidin (accessed on Oct. 29, 2019) 
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1.6. Cranberry and lingonberry health effects  
 
In the past, cranberry has been used for many different health problems, including fever, blood 
disorder, stomach ailments and liver problems. Cranberry was typical natural medicine for Native 
Americans (Raz et al., 2004). 
Studies done with spontaneously hypersensitive rats have shown that lingonberry lowers elevated 
blood pressure (Kivimäki et al., 2019). Lingonberry has also been shown to balance an otherwise 
unhealthy diet. In a study done with mice who had an unhealthy fatty diet comparable to humans, 
lingonberry prevented diet-induced obesity and low-grade inflammation. A reason for such results 
seems to be lingonberry effects on gut microbiome. Abundance of genera Akkermansia and 
Faecalibacterium, which are associated with healthy gut mucosa and anti-inflammation, increased 
by lingonberry consumption (Heyman-Lindén et al., 2016).  
Antioxidant compounds of genus Vaccinium inhibit oxidation of low-density lipoproteins and 
reduce oxidative and inflammatory damage to the vascular endothelium. Studies done with mice have 
shown that cranberry polyphenols improve glucose and lipid homeostasis during high-fat and high-
sucrose diet (Rauf et al., 2019; Jurikova, 2018).  
PAC effect on colonic health has been studied with pig models that have a similar gastrointestinal 
tract as humans. In one study, six pigs were given 1% (w/w) of MegaNatural® Gold grape seed 
extract (GSE) once a day for six days. DNA was extracted from fecal samples and sequencing was 
done by using 16S rRNA barcode markers. Results showed that the major microbial metabolism 
products were 4-hydrophenylvaleric and 3-hydroxybenzoic acid, as their content in samples increased 
during treatments. The diet also caused an ecological shift in the pig gut microbiome, as Clostridiales, 
Lachnospiraceae, Lactobacillus and Ruminococcacceae abundance increased (Choy, Y. et al., 2014). 
There is also some evidence about efficacy of cranberry PACs, quercetin and ursolic acid, against 
tumor development by inhibiting proliferation and colony formation, inducing apoptosis, and limiting 
tumor ability to invade. PACs also relax vessels and inhibit low-density lipoprotein oxidation, which 
can benefit health in case of cardiovascular disease (Cardano, 2013). However, more animal and in 
vivo studies are needed. 
Although most PACs are not absorbed into bloodstream but are extracted into urine, as has been 
shown they can produce a health effect. Oligomeric and polymeric units have antioxidant and anti-
inflammatory properties. PACs, formed of several monomers, can bind to excess activated enzymes, 
which are typical for the inflammatory condition. They have also a structure to attach to and increase 
barrier integrity, and large PACs can regulate cell signaling pathways by interacting with cell 
membrane proteins (Choy et al., 2014). 
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1.7. PAC metabolism in human 
 
PACs, like other ingested polyphenols, are treated like xenobiotics in the body. This is because they 
are not a natural ingredient of the human body. The intestinal absorption of PACs is poor due to their 
structure and high molecular weight. Their decomposition is highly dependent on stomach pH value. 
They might be acid-catalyzed to monomeric flavan-3-ol units in the proper gastric environment 
(Spencer et al., 2000).   Minor PAC monomers and dimers can be absorbed in the small intestine by 
Caco-2 epithelial cells, and studies have shown low plasma concentrations in patients after ingestion.  
Before absorption to bloodstream, compounds are first circulated in the liver where they are 
methylated, sulfated or glucuronidated by transferase enzymes. More studies have been done with B-
type PACs (B1-B2), but studies in rats show that AC-PACs (A1-A2) are better absorbed in the small 
intestine than B2 PACs (Choy et al., 2014).  
More complicated PACs, polymers and oligomers, are not absorbed and continue their pathway 
to the colon where microbial metabolism breaks down the compounds into smaller units. The body 
can absorb those to the bloodstream, but less is known on how cells can utilize their beneficial 
antioxidant properties. Overall, over 90 % of ingested polyphenols continue their way to the colon, 
where microbial metabolism seems to play a major role (Cassidy & Minihane, 2016). 
Absorption of antioxidant compounds in intestine is typically limited. According Professor Lars 
Porskjær Christensen, from The University of Southern Denmark, antioxidant concentration in blood 
is very low, because most antioxidants have difficulties in passing through the cell membranes. 
Compounds of relatively polar and structural complexity must first be degraded and made less polar. 
He also criticizes typical belief on how antioxidants work in the body in the same way as in vitro 
studies, because many compounds are environmentally dependent. For example, vitamin C can work 
both as antioxidant or pro-oxidant. Christensen highlights that antioxidants are formed in the liver 
and for the most parts rapidly excreted in the urine, and how the remaining portion works and is 
absorbed to cells is still a mystery in many ways (Christensen et al., 2018). 
 
1.8. Role of colonic microbiome in polyphenol metabolism 
 
Diet effect on the gut microbiome has been studied a lot in recent years. For example, the diet has 
been shown to cause ecological migration in the gut microbiome. The number of known microbes 
that can utilize and catabolize biochemical compounds in the diet is increasing. In this way, human 
body is able to utilize many compounds that were initially too big to absorb. For microbes, these are 
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typically only by-products of metabolism that are utilized to buy space in a symbiotic microbial 
community (Chen et al., 2014).  
In 2013, only a few bacterial species were identified to catabolize polyphenols (Cardona et al., 
2013). These included Escherichia coli, Bifidobacterium sp., Lactobacillus sp., Bacteroides sp. and 
Eubacterium sp.. Only couple of years later more species were identified more accurately being 
involved in metabolism of polyphenols. Adlercreutzia equolifacients can dehydroxylate flavan-3ols, 
Eggerthella sp. SDG-2, Eggerthella lenta, Slackia equolifaciens, Adlercreutzia equolifaciens and 
Lactobacillus plantarum are shown to cleave C-ring from catechin and epicachin (Cardona et al., 
2013; Braune & Blaut, 2016).  
PACs are catabolized to chain fission products by intestinal bacteria. For example, 3-
hydroxyphenyl acetic acid, 3,4-dihydroxyphenylacetic acid, 3-(3-hydroxyphenyl) propionic acid, and 
5-(3′-hydroxyphenyl)-γ-valerolactone compounds are metabolites of PAC cleaving microbes among 
human microbiome. In these forms, they may be absorbed by the body, but their exact effects are still 
not well known (Cardona et al., 2013).  
The effect of cranberry AC-PACs on the intestinal microbiome in-vitro has been studied in a 
project to develop nutrition strategies in the military environment (Laurel et al., 2018). Bacteria were 
extracted and grown from feces of three individuals in a nutrient-rich anaerobic medium 
supplemented with purified cranberry PAC at low and high doses. Results show that PAC might have 
a prebiotic effect on gut microbiome. Laurel et al. (2018) found out that abundance of Ruminococcus 
spp., which are associated with resistant starch degradation in the colon, was dose-dependently 
increased (p<0.05). Results also showed that butyrate production is PAC-dependent. PAC-dependent 
bacterial growth was revealed to be domain-dependent in studies that stimulate environmental 
conditions in different intestinal regions/domains (Laurel et al., 2018).  
 
1.9. Polyphenols affecting microbiome composition 
 
The exact information on the effect of polyphenols on gut microbiome is still low. Estimated different 
microbial species number ranges between 500-1000 in the gut microbiome, and their interactions 
with polyphenols are still a mystery. Some evidence has shown that dietary polyphenols affect 
microbial population composition and microbial activity. Most studies have focused on single 
polyphenol compounds and their effect on selected bacterial populations (Cardona et al., 2013).  
Polyphenols have a positive effect on gut microbial content, and their abundance may alter 
Bacteroidetes/Firmicutes ratio (Stoupi at al., 2010). The effect of polyphenols was tested by a batch-
culture model reflective of the distal region of the human large intestine, and the study showed that 
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flavan-3-ol monomers enhanced the growth of E. coli and bacteria in the Clostridium coccoides-
Eubacterium retale group and inhibited the growth of Clostridium histolyticum (Tzounis et al., 2008). 
There are also more in vitro and in vivo evidence that flavan-3-ols may inhibit Clostridium spp. and 
favor Lactobacillus spp. (Cardona et al., 2013). 
Phenolic extract of eight berries inhibits the growth of food-poisoning bacteria, that are 
pathogenic to humans, in a laboratory environment. Results showed that pathogenic strains were 
selectively inhibited. Cloudberry and raspberry extracts were the best inhibitors of bacterial growth, 
where the most effective compounds were ellagitannins. The extracts worked best against 
Staphylococcus but had no effect on probiotic bacteria Lactobacillus rhamnosus, indicating that the 
antibacterial effect is selective on pathogens. Only cranberry extract inhibits Listeria strain 
(Puupponen-Pimiä et al., 2005).  
Another study showed that a 20-day treatment with polyphenol-rich red wine increased the 
relative abundances of the phyla Proteobacteria, Actinobacteria, Fusobacteria, Firmicutes, and 
Bacteroidetes found in fecal samples during treatment. Interestingly, non-alcoholic red wine only 
increased Fusobacteria and Bacteroidetes abundances (Queipo-Ortuño et al., 2012).  
 
Many questions remain open, such as the role of microbial metabolites in humans and the mechanism 
leading to individual differences in the gut and urinary tract microbiomes. Relationship between the 
diet and microbiome has been shown, but the exact mechanisms are unclear. Microbiome and 
microbial metabolites seemingly modulate host health, but this crosstalk is still an ancient language 
that is under radical investigation (Wang et al., 2019). 
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2. Aims of the study 
 
Cranberry has long been known to contain many health benefits as a source of nutrition, and 
especially in preventing urinary tract infection. However, the key to how this is happening is still 
mostly a mystery. Earlier studies have shown that there might be a connection between gut 
microbiome and urinary tract infection (Paalanne et al., 2018). 
In this study, children with urinary tract infection were randomized to Cranberry-Lingonberry 
juice (CLJ) and control (flavonoid-free juice) consumption groups. Hypothesis was that the 
metabolism of proanthocyanidins in the gut alters bacterial composition and reduces the amount of E. 
coli and possibly other proteobacteria in the urine. The specific aims were 
1) To compare microbiomes of the CLJ and control groups 
2) Identify key microbes/groups 
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3. Materials and Methods 
3.1. Samples and juices 
 
Feces and urine samples were collected by the Oulu University Hospital Children's Clinic. Total of 
77 children participated in the study. There was one real treatment, so the two groups were formed 
from patients, and one group drank Cranberry-Lingonberry juice (CLJ), and the other a control juice 
without cranberries. Research time was one year, and feces samples were collected after three -, six 
and twelve months. Urine samples were collected after three months. The assumption was that the 
changes would be identified in the urine sample after three months of CLJ use and to defined longtime 
effect in gut microbiota longer research time is needed. 
Groups were coded by numbers. Number 1 was used to control group, and number 2 for CLJ 
group. Group 1 consisted of 116 samples from 42 patients and group 2 consists of 89 samples from 
35 patients. Also, two samples were without tags. The total sample count was 207, including feces 
and urine. 
Cranberry-Lingonberry juice (CLJ) used in this research, containing 2.0 g cranberry concentrate, 
1.8 g of lingonberry concentrate with flavors, and 10.0 g sugar per one deciliter of juice. Placebo 
juice that control group used contained 10.2 g of added sugar, 5.5 g of citric acid, 5 g of natural 
cranberry aroma and 1 g of red anthocyanin color in one deciliter. It tastes, smells, and has the same 
color as CLJ but does not contain berry extracts. Juice products were provided by Eckes-Granini 
Finland. 
 
3.2. DNA extraction 
 
The DNA extraction was performed using two commercial extraction kits. For fecal samples, 
commercial QIAamp DNA stool kit was used. Extraction was performed manually according to the 
QIAamp handbook manual. In one extraction process, four to twelve samples were processed.  
After fecal sample DNA extraction, the concentration of DNA quantity (ng/ul) and quality was 
measured by taking an A260/A280 and A260/A230 ratios, using Nanodrop spectrophotometer, 
(Thermo Fisher, USA). If yielded material was less than 20 ng/µl and quality seemingly bad, the 
sample was processed again. After verifying the success of the extraction, all extracted DNA sample 
materials were stored to -20 °C.  
The extraction procedure can be divided to main points. First, Buffer ASL were used to lysis stool 
samples. Sample-buffer-mix were homogenized by vortex and stool lysate were add. Heat were used 
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to increase bacterial cells lysis. Heated mix were centrifuged to produce supernatant for later use. In 
the next steps, PCR inhibitors and DNA-damaging substances were absorbed from supernatant.  
Last, DNA in the supernatant is purified. Procedure involves a couple of steps. First, proteins were 
digested, then DNA was bound to QIAamp silica membrane. The membrane was washed a couple of 
times to remove impurities before pure DNA is eluted to buffer that can be later used for PCR. 
Urine samples were also extracted manually according to the extraction kit manual with some 
modification. For the extraction process, supernatant and pellet were made of urine samples. Pellet 
was used in later extraction process steps, which were mainly similar than with stool samples. Due to 
the different composition of sample material, the reactants, heating - and centrifugation times were 
mostly different for different sample materials. Urine volume varied clearly between samples. 
Quantity and quality of isolated DNA were also defined by Nanodrop. All extracted DNA samples 
were stored – 20 °C for later processing.  
 
3.3. PCR 
 
Before PCR, extracted microbial DNA samples were diluted to concentration 5 ng/ µl in a total 
volume of 50 µl and stored at -20 °C. For dilution calculations, data from Nanodrop was used. 
Samples that had lower yields were used without dilution. Later, the diluted samples were pipetted 
on a 96-well sample plate. Using a 96-well sample plate proved to be a better option than 1.5 ml 
Eppendorf tubes for PCR plate preparation.  
For PCR, the master mix was made according to Table II recipe. Mastermix total volume 
depended on the number of samples to be amplified. Also, negative control samples and pipetting 
error were taken to account when planning master mix volume for the PCR process. All other reagents 
than barcoded reverse-primers and the sample DNA were mixed in 1.5 ml Eppendorf tube. The 
samples were spun down in a centrifuge to ensure mixing. dNTP mix of 10 mM were mixed and 
diluted from 100 mM nucleoside triphosphate solutions using Hypure Molecular biology grade water 
(Table I). The same water was used for master mix and diluting forward primer from stock. Reverse 
primers were already diluted to 10 mM or 5 mM.  
Master mix was loaded to the 96-well plate by pipet or a multipipet. PCR-reaction was done in 
triplicate. Negative controls were used to test purity of reagents so that possible source of 
contamination could be found and eliminated. In negative controls, DNA was replaced by sterile 
water. One to three negative samples were added per plate depending on sample count.  One 96-well 
plate could handle 29-30 samples and two to three controls. First, the mixed reagents were added to 
plate, followed by the unique barcode reverse-primer and finally DNA. Information about used 
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barcode reverse-primers and DNA samples were recorded for later purpose. Barcode primers were 
later used to target DNA sequences to the correct samples. 
Table I dNTP mix 
dNTP mix    
reagent (concentration) volume  final concentration  manufacturer 
dH20 60  µl   
dATP (100 mM) 10  µl 10 mM Thermo Fisher 
dTTP (100 mM) 10  µl 10 mM Thermo Fisher 
dGTP (100 mM) 10  µl 10 mM Thermo Fisher 
dCTP (100 mM) 10  µl 10 mM Thermo Fisher 
Total 100 µl     
 
Table II PCR Master mix 
PCR Master mix 
   
reagent (concentration) volume  final concentration  manufacturer 
dH20 8. 9 µl or 7.9 µl   
PCR buffer Phusion GC (5X)  4 µl 1 X Thermo Fisher 
DMSO 0.5 µl 2.5 % Thermo Fisher 
dNTP mix (10 mM) 0.4 µl  200 µM Thermo Fisher 
forward primer F519 10 mM or 5 
mM 1.0 µl or 2.0 µl 500 µM Thermo Fisher 
reverse primer R926 10 mM 1.0 µl  500 µM Thermo Fisher 
Phusion Polymerase 5 U/µl 0.2 µl  1 U Thermo Fisher 
DNA (5 ng/µl) 4 µl   20 µg  
Total 20 µl     
 
 
Table III PCR reaction protocol 
 
 
 
 
 
 
 
 
 
 
 
 
Temperature Time 
Initial denaturation: 98 ℃ 3 min 
35 Cycles: 98 ℃ 10 s 
 
64 ℃ 15 s 
 
72 ℃ 30 s 
Linked to: 72 ℃ 7 min 
Hold: 4 ℃ ∞ 
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Reagents, samples and plates were kept on ice throughout the preparation of the PCR. After 96-
well plate was loaded, it was covered with a sealing tape. PCR-reaction was processed with Applied 
Biosystems Veriti 96 Well Thermal Cycler (Thermo Fischer) using the PCR protocol showed in Table 
III. After PCR-reaction was done, three identical reactions were combined into one, comprising a 
total volume of 60 µl. From that, 15 µl were analyzed by agarose gel electrophoresis. The rest of the 
PCR-product (45 µl) was stored at -20 °C. 
 
3.4. Electrophoresis 
 
A 1.4 % TBE (Tris base, boric acid and EDTA)- agarose gel was prepared for electrophoresis. 3 µl 
Ethidium bromide (10 mg/ml) was added to 50 ml liquid agarose gel, and mix was poured into the 
plate and left to cooldown. The ratio was same for every gel. Ethidium bromide was used to visualize 
the DNA in agarose gel after gel electrophoresis. When it intercalates between the nitrogenous bases 
of DNA, the DNA can be visualized under UV light. 
The 15 µl of PCR samples were mixed with 3 µl DNA Loading dye (5X) produced by Thermo 
Fisher. In addition to the PCR samples, a DNA size standard for 16S by Thermo Fisher was loaded 
into the gel in total volumes of 18 µl. BioRad Power Pac 200 was used as the power supply and 
electrophoresis was performed for 1 hour at 100 V. If the PCR-reaction was successful, 16S bands 
could be visualized on the gel under UV light.  
16S rRNA genes are widely used in phylogenetic studies, because it contains hypervariable 
species-specific sequences that can be used for identifying. In this case 16S clone products can be 
amplified from agarose gel according to typical size of the product. No products in negative controls 
ensured that the reactions were free from contamination and only 16S part of bacterial DNA was 
cloned (Yarza et al., 2014).  
The electrophoresis gel images are shown in the Appendix 1. At its best, gel included 24 triplicate 
samples and three triplicate negative controls. Loading order and sample/barcode numbers are 
marked in the images. For clarity, a ladder was always added to the first well of each row. 
 
3.5. Next-generation sequencing 
Sequencing is used to transform the extracted 16S rRNA gene sequence information from samples to 
sequence library. In this study, 16S ribosomal RNA (rRNA) gene sequencing technique and reverse 
primer set F515-R926 were used. The 16S ribosomal RNA gene contains regions that are species-
specific. F515-R926 primer set contains the regions V4-V5 of nine multivariable regions of bacterial 
16S ribosomal RNA gene. In PCR-reaction, the primers were used to build up several copies of 
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species-specific 16S strands, and by using sample-specific barcode primers, it’s possible to pool all 
samples together into one library dataset (Chakravorty et al. 2007; Joe et al., 2016). 
Ion Torrent next-generation sequencing (NGS) platform (Thermo Fisher) was used to sequence 
16S rRNA gene from the PCR-products. For that, the PCR-product samples were collected on a new 
96-well plate by diluting them to a total volume of 50 µl. After all samples were transferred to new 
plates, they were sequenced at Biocenter Oulu Sequencing Center. 
Ion Torrent NGS process starts with fragmenting a PCR-product DNA into millions of fragments. 
Those fragments are then labelled and cleaned from unwanted salts, enzymes and smaller fragments. 
After purification, each DNA fragment is bound to an ion sphere particle (ISP) and the binding is 
repeated until the ISP is covered with multiple copies of the same DNA fragment. The fragments are 
linked at one end of the ISP and biotinylated at the other end. That side will bind to magnetic beads 
so that empty ISPs are washed away. Enriched ISPs are then put to chips and sequencing can start 
(Rusk, N. 2010; Merriman, B. et al., 2012). 
Ion Torrents semiconductor chips are full loaded with wells that capture chemical information 
from DNA sequencing and translate it to a digital form. Every time nucleotide is incorporated into a 
single strand of DNA, a hydrogen ion is released. This will lead to a change in pH in wells, and that 
change can be recorded and translated to a digital format (Merriman, B. et al., 2012; Rusk, N. 2010). 
Semiconductor chips are covered with liquid of one of four DNA nucleotides at a time. Nucleotide 
liquid is chanced every 15 seconds.  A polymerase is used for connecting those nucleotides to a single 
strand of DNA. Every time when nucleotide incorporates into strand of DNA, pH change is measured 
and chanced to voltage. If there are two or more same complementary nucleotide in a strand of DNA, 
voltage is higher, and count can be recognized. The same process happens simultaneously in millions 
of wells. In the end, every attached nucleotide is recorded and translated to human-readable digital 
information (Rusk, N. 2010; Merriman et al., 2012). 
3.6. Data processing  
3.6.1. Metadata 
 
For analyzing data build up with Ion Torrent NGS, metadata is formed. Metadata contains sample 
tags by rows and columns contain associated information. For QIIME 2 platform, first column has to 
include sample identification number (#SampleID). Barcode sequences and forward primer 
sequences must be inserted in the table. Other columns may include valuable information about 
samples e.g. treatment, sample material, age, sex etc. that can be used in statistical analysis.  
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In this study, information about treatment - and research groups, sample materials and collection 
time were used. The metadata was collected and are provided by the University Hospital of Oulu. An 
open-source Google Sheets add-on Keemei were used to validate QIIME 2 compatibility (Bolyen et 
al. 2018). 
 
3.6.2. QIIME2 
 
QIIME 2 is plugin compatible microbiome analysis software. The software produces and uses 
QIIME 2 artifacts (.qza). By using this file format, the software can track the type, format and 
provenance of data for researchers. QIIME 2 works via Python. QIIME 2 artifacts can also be used 
to build Visualization from analysis results. Visualization can be viewed using the qiime2view 
interface. 
Fastq-file produced by Ion Torrent was imported to QIIME 2 environment where the software 
was used to study and edit sequence information. Pooled sequences were demultiplexed, and 
metadata were used to connect right samples and sequences. Sequences were trimmed to 300 bp and 
sampling depth of 32200 was selected for downstream analysis.  
For taxonomic analysis, Silva 132, Greengenes and Human Oral Microbiome Database (HOMD) 
were used as 16S sequence reference data. There weren’t major differences between the identified 
taxa in Silva 132- and Greengenes database, but taxonomy table produced with Silva worked better 
in the downstream analysis done by R. 
 
3.7. Statistical analysis 
 
For the microbiome analysis, QIIME 2 artifacts were changed to a format that can be handled by R 
programming language. QIIME2R is an R package for importing QIIME 2 artifacts into an R session. 
In this study, table.qza, rooted-tree.qza and taxonomy.qza artifacts and metadata.tsv file were used to 
build up phyloseq object. Phyloseq object stores all produced and OTU (operational taxonomic unit) 
clustered phylogenetic data into one R object. QIIME2 use DADA2 plugin to produce OTU artifact 
and strictly speaking those are ASVs (amplicon sequence variant) which are higher resolutions and - 
quality sequences. Although ASVs are a hash (a coded string of numbers and letters that represents 
unique sequences) and can be used to compare datasets denoised with exact same parameters.  
The phyloseq package was used to analyze and graphically display sequence data. It leverages 
many other R tools for phylogenetic analysis and use ggplot2 graphic system. In this study, ALDEx2, 
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cowplot, metacoder, microbiome, phyloseq, tidyverse, vegan and ggplot2 packages were used to 
produce graphics of complex phylogenetic data (McMurdie & Holmes, 2013). 
 
3.7.1. Relative abundance 
 
Samples were divided by sample material, collection time and treatment into eight groups. This 
enabled comparison of long-term changes in gut microbiome between treatments.  
After subgrouping, low abundance and unidentified phyla were filtered. Prevalence threshold of five 
percent was selected to remove ASVs which were present only one sample. 
 
3.7.2. Alpha diversity 
 
Alpha diversity is a local measure and describes diversity in a particular ecosystem. It can tell about 
the number of species in an environment under certain conditions. In this study, we were interested 
about Alpha diversity in gut and urinary tract microbiome after different treatment conditions. Alpha 
diversity was measured from microbiome of feces and urine samples in control and CLJ groups. 
Observed species richness is one way to show Alpha diversity, but many different diversity indexes 
diversity indexes that can provide more information about community composition. Different indices 
have different assumptions and weights. The best index most often depends on the study design, and 
various indices give more perspective (Tuomisto, 2010). 
In this study, various indices were used to show community richness in different conditions. Any 
observed rare ASVs were not trimmed before analysis because it can seriously alter the results. Some 
estimators give weight also for rare species.   
The Shannon index assumes that all species are represented in a sample and are randomly 
sampled. It is a statistical information index and it shows how difficult it is to predict the identity of 
the randomly chosen individual. The Simpson index is a dominance index, meaning that it gives more 
weight to common or dominant species. It answers the question on the probability if two randomly 
selected individuals are of the same species. Chao1 is an abundance-based coverage estimator of 
species richness (Lee and Chao, 1994). Chao1 estimator takes into account the estimated number of 
unobserved species. Inverse Simpson estimator is inverse of the probability that two bacteria picked 
at random in the community belong to different OTU (Tuomisto, 2010).  
Shapiro-Wilk normality test was used for observed and Chao1 estimator data in every group, to 
analyze distribution. Skewness plots were also built for studying the skewness of data (Figure 4). If 
data was not distributed normally, the Wilcoxon rank-sum test was used to test Alpha diversity 
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differences statistically. Wilcoxon rank-sum test is non-parametric test of the null-hypothesis that 
randomly selected ASV abundance from one sample is lower or greater than a random selection from 
another group. T-test was used for analysis of data with normal distribution. 
 
3.7.3. Beta diversity 
As the Alpha diversity describes how many different species there are and how balanced those are in 
a sample, beta diversity shows how different the microbial composition in one sample is compared 
to another. There are different metrics for beta diversity than alpha diversity. 
Bray-Curtis and weighted UniFrac metrics take abundance into account, Jaccard and unweighted 
UniFrac only calculate beta diversity based on presence-absence data of an OTU/ASV. OTU-based 
metrics ignore taxonomy. Unifrac metrics incorporate phylogenetic information by using 
phylogenetic tree information about sequence distances. Unweighted branch is based on sequence 
distances, and weighted branch lengths are weighted with relative abundances (Tuomisto et al., 2010). 
3.7.4. Differential abundance 
 
Differential abundance was studied by metacoder and phyloseq R-package. The target was to identify 
significantly differentially abundant taxa for the treatment groups in the four different sample types. 
ANOVA-like differential expression (ALDEx2) method was used to test differentially abundances in 
ASVs between the treatment groups. This is a version of the Wilcoxon test developed for 
compositional NGS data (Gloor, 2015). 
Metacoder-package for R was used to build differential heat trees from CLR-transformed data. 
Data were cleaned from unidentified and low abundance taxa before plotting. The tree branches 
represent identified taxa up to the species-level. The width of the branches was used to illustrate the 
amount of OTUs (ASV), and color panel was used to indicate which treatment has greater abundance 
using CLR-transformed data (Foster et al., 2015). 
Differential abundance was also studied by QIIME 2 using phylum- and genus-level identification 
results. 
 
3.7.5. Compliance 
 
Clinical compliance data was used to trim the sample data of the time point of three months. 
Compliance shows the probability that patients had really used medication. The cut-off value was set 
at 80 %. After taking clinical compliance into account, there was a total of 54 samples left for 
 
22 
 
downstream analyses. CLJ group contained 29, 18 fecal and 11 urine, and control group 29 samples, 
22 fecal and 7 urine.  
After trimming, three-month samples were statistically analyzed by using the above-mentioned 
methods. Krona plots were used to visualize differential abundance between two treatments in feces 
and urine in the three-month samples. 
4. Results 
4.1. DNA extraction and PCR 
 
DNA was extracted from 202 samples. Samples 100, 112, 204, 32, 33, 42, 69, 74, 86, 96 and 97 were 
re-processed, because low concentration results and there was sufficient amount of sample material 
to re-run.  Three fecal samples contained an insufficient amount of sample material for DNA 
extraction. Two urine samples from hospital list were missing and one fecal sample falcon was empty. 
There were also three samples that were missing from the list. The average DNA yield from urine 
samples was much lower than that in fecal samples, as could be expected. Of all extracted samples, 
47 had < 20 ng/ul concentration and were used without dilution in PCR. 
PCR results are shown in Figures in the Attachment (Attach 1), and one example is shown in 
Figure 2.  After NGS sequencing, there were a total of 115 samples in control group (1), of which 96 
were feces and 19 urine samples. CLJ group (2) had 71 feces and 17 urine samples, 88 in total. After 
removing duplicates, a total of 197 samples were processed for downstream analysis.  
 
 
23 
 
   
 
4.2. Relative abundance 
 
Prevalence filtering caused a drop of 13 samples in the total count (184). In the Figure 3 groups of 
different treatments, but the same sample material and collection time, are presented side by side to 
allow easy analysis of any differences between treatments phylum-level relative abundances. Every 
analysis was produced according to the same grouping. 
Phylum-level relative abundances were pretty similar between treatments. Bacteroidetes and 
Firmicutes play a dominant role in the majority of the samples. However, there were differences in 
the Bacteroidetes/Firmicutes ratio that could not be explained by treatment. Also, some samples 
contained Cyanobacteria that were not typically found in other samples. Actinobacteria were typically 
found almost in every sample. An interesting difference can be seen in urine sample groups. 
CLJgroup samples had less Proteobacteria members, and more of those belonging to Firmicutes.  
Figure 2 Agarose gel electrophoresis of PCR products amplified from bacterial 16S rRNA genes. The 1.4% agarose 
gel was made in TBE buffer, which was used in the electrophoresis at 100V for one hour. The samples are 
numbered above each well. The DNA molecular weight standard (st.) was GeneRuler DNA Ladder Mix (Thermo 
Fisher). 
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Figure 3 Phylum-level relative abundances in sample type groups. A=Urine 3 months samples, B: Feces 3 months, C= 
Feces 6 months, D=Feces 12 months.  All feces groups have same legends, and urine owns. Plots are facet by treatments 
1=control & 2=CLJ.
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4.3. Alpha diversity 
 
Skewness of sample groups data are 
showed in Figure 4. Observed, Shannon, 
Simpson, Inverse Simpson and Chao1 
diversities are presented in Figure 5 
boxplots. ANOVA and Wilcoxon rank-sum 
test results are shown in Table IV. Feces 3 
months sample data was not distributed 
normally, but the data in other three groups 
was normally distributed. There was no 
significant difference between treatments. 
As can be seen, most differences are found 
between sample types. 
 
 
 
 
Table IV Alpha diversity indices with significance tested by t-test or Wilcoxon test 
Group Observed Chao1 Shannon Simpson InvSimpson 
  Wilcoxon rank sum test, p-value 
 Feces 3 months 0.84 0.84 0.92 0.82 0.82 
   t-test, p-value 
 Feces 6 months 0.8746 0.9416 0.7988 0.4765 0.3587 
 Feces 12 months 0.6039 0.8238 0.6277 0.592 0.9618 
 Urine 3 months 0.4525 0.6814 0.8017 0.8319 0.6901 
Figure 4 Plots of skewness of different sample groups. Urine 3 - 
and feces 6 and - 12 months samples are distributed normally, and 
feces 3 months are not distributed normally according to these 
plots and Shapiro-Wilk normality test. A=Urine 3 months, B= 
Feces 3 months, C= Feces 6 months, D=Feces 12 months.  
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Figure 5 Alpha diversity metrics. Each measure is listed above each plot, and x-axel contains groups. Groups are divided 
by treatment, sample material and collection time in months. Last two are shown also as a color code: Green indicates 
urine samples, dark green indicates 3 months feces samples, blue indicates six months feces samples and red indicates 
twelve months feces samples.Y-axel  contains abundance metrics values. 
 
4.4. Beta-diversity 
In this study, The Bray-Curtis dissimilarity metrics were used to build dendrogram from samples 
relative abundance data (Figure 7). The Bray-Curtis dissimilarity gets the value zero when the 
composition between samples is exactly the same, and one, when no taxa are shared. The treatment 
groups were color coded, control treatment (1) in red and CLJ treatment (2) in blue. 
Beta diversity ordination in different sample types was generated using centered log-ratio 
transformed (CLR) counts. Transformation was performed using Microbiome R-package. Principal 
component analysis (PCA) histogram shows how much of variation are explained by first two 
principal components compared to other PCs (Figure 6). Those two PCs were mapped to two-
dimensional space. Every group had some differences between treatments, and overlapping is typical 
for the same environment samples. Therefore, the beta-diversity analysis was continued further. 
Permutational multivariate analysis of variance (PERMANOVA) was used to test if there is more 
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clustering than expected by sampling variability. Homogeneity of multivariate dispersions were 
tested by ADONIS test, and for results, a permutation-based test was performed. Results are showed 
in Table V and Figure 8.  
There were no significant differences in beta diversity indices between the treatment groups. The 
dendrogram shows that there is no partitioning between the treatment groups. 
Ordination centroids and dispersion labeled method shows that there are no remarkable differences 
between ordination centroids and dispersion. The greatest differences can be seen in the six-months 
sample group. 
 
 
 
Figure 6 X-axel contains PCs formed from data, y-axel shows proportion of 
variance. Typically, first component includes most variance and after drop 
that continues gradient degree. In this study, drop isn’t particularly huge. A= 
Urine 3 months, B= Feces 3 months, C= Feces 6 months, D=Feces 12 months) 
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Figure 7 Bray-Curtis dissimilarity shows how different the samples in treatment groups are to each other. Samples under 
control treatment (1) are marked in red, samples under CLJ-treatment (2) are marked in blue. The longer the distance is, 
the more different is beta diversity between the treatments. A=Urine 3 months samples B: Feces 3 months, C= Feces 6 
months, D=Feces 12 months 
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Figure 8 Beta diversity. Ordination centroids and dispersion labeled Aitchinson distance were used to illustrate beta 
diversity of samples in different treatments using two PCoA. Grey indicates control-treatment (1) and red indicates CLJ-
treatment (2) plots. A=Urine 3 months samples B: Feces 3 months, C= Feces 6 months, D=Feces 12 months 
 
Table V Beta diversity metrics 
  Urine 3 months Feces 3 months Feces 6 months Feces 12 months 
ADONIS, p-value 0.997 0.698 0.283 0.756 
Dispersion test / T1 & T2 24.16 & 23.69 33.23 & 33.26 31.40 & 31.08 32.03 & 32.09 
Permutation test, p-value 0.753 0.984 0.784 0.973 
 
 
4.5. Differential abundance 
 
ALDEx2 test results are presented as effect size plots (Figure 9) that show no significant differences 
in abundance between treatment groups according to microbiome data. For a difference in taxa 
abundance to occur, it should exceed the dispersion. Benjamini-Hochberg false discovery rate (BH-
FDR) corrected p-values should be present as red plot for taxa if those fall below the significance 
threshold (<0.05). 
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The effect size plots show the median log2 fold difference by the median log2 dispersion in every 
sample material time point. Differences between treatment groups can be read from y-axel. Data 
points plotted towards the bottom of the plot are more abundant in CLJ samples, and data points 
plotted towards the top of the plot are more abundant in control group. In every subgroup, there is a 
cluster in the middle of y-axel indicating that the abundances in the treatment groups are mostly 
similar by dispersion. The division on both sides of the y-axis origo shows different concentrations 
between the treatment groups, although not statistically significant. This is especially visible in urine 
plot. Dispersion in every treatment group is, overall, very similar. 
  
 
Figure 9 The effect size plots. Significantly different ASV should be plotted with red and wider diameter. A=Urine 3 
months samples B: Feces 3 months, C= Feces 6 months, D=Feces 12 months 
Species-level differences are shown in Figure 10 with heat tree plots containing CLR-transformed 
abundances for every treatment group. Log2 transformation was done to modify data divided by 
treatment to symmetric around zero. Species that were more abundant in control group (1), got 
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positive values and were colored turquoise. Species that were more abundant under CLJ treratment 
(2), got negative values and were colored tan. Differential abundance can also be seen from lower 
taxonomic nodes by the same rules. If there was no difference between treatments, the value became 
zero. Due to natural variation, exactly the same value is rare and small differences are always found.  
Differential abundance for ASV in the different treatment groups were tested by Wilcoxon rank 
sum-test. There were no significant differences after false discovery rate (FDR) correction. Heat trees, 
containing log 2 ratios of median proportions and OTU/ASV counts were used to visualize species 
richness in sample types (Figure 10).  
 
Figure 10 Heat tree maps containing centered CLR-transformed differential abundances between treatment groups. Value 
zero means no differences in abundance between treatments, distance from that shows difference level and direction. 
Turquoise-colored nodes indicate more abundance under treatment 1(control) and tan nodes under treatment 2 (CLJ). 
Node width shows OTU-count (ASV). A= Urine samples, three months, B= Feces samples, three months, C=Feces 
samples, six months, D= Feces samples, twelve months. 
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Kruskal-Wallis - and Mann-Whitney test results from phylum and genus-level data showed no 
significant differences between treatment groups in any subgroup.  Some p-values reached the level 
of significance at genus-level in every subgroup, but after BH-FDR correction, the levels of 
significance were lost.  
 
4.6.Compliance 
 
Alpha – and Beta diversity were not significantly different between CLJ- and control treatment groups 
even when a compliance limit of 80 % was taken into account (data not shown). Differential 
abundance was also tested by Aldex2 -method, which showed no significant differences between 
ASVs. Besides the dispersion in urine samples being wider with compliance limit, there was no 
change in results (data not shown).  
Krona plots (Figures 11-12) show relative abundances for data with compliance limit of 80 % in 
use. According to the Krona plots of urine samples, there are differences in abundance of some phyla 
and families between treatments. Proteobacteria were less abundant and Firmicutes were more 
abundant in the CLJ group. The CLJ group also had 5 % less members in the family 
Enterobacteriaceae (taxonomic family level under Proteobacteria phylum) than control group.  
The krona plots (Figure 11-12) of the feces samples at three months were mainly similar between 
CLJ and control group after 80% compliance limit correction. However, some differences can be 
seen, e.g. the CLJ group has lower abundance of Proteobacteria compared to the control group. 
QIIME2 environment was used to do Mann-Whitney and Kruskal-Wallis test for phylum and 
genera level taxa in both sample material groups. Mann-Whitney test for urine samples in genera 
level showed that genus Finegoldia had significantly different abundance between treatment groups. 
There were also some other statistically significant findings where the raw p-value was under 0.05, 
but these were lost after BH-FDR. Mann-Whitney test for feces samples in phylum level showed that 
the phylum Cyanobacteria had significantly different abundance between CLJ – and control group. 
Similarly, some findings at genera level had raw p-values under 0.05. All results are shown in table 
VII. 
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Table VII QIIME2 tests results 
Urine 3 months    
MannWhitney- Urine       
Genus Reject Statistic raw pvalue 
Finegoldia True 38.5 0.0080 
KruskalWallis- Urine       
Phylum Reject Statistic raw pvalue 
Proteobacteria False 4.1957 0.0420 
MannWhitney- Urine       
Genus Reject Statistic raw pvalue 
Fastidiosipila False 38.5 0.0230 
Negativicoccus False 38.5 0.0200 
 
 
 
Feces 3 months   
MannWhitney       
Phylum Reject Statistic raw pvalue 
Cyanobacteria True 197.5 0.0100 
KruskalWallis-Feces       
Phylum Reject Statistic raw pvalue 
Actinobacteria False 4.2193 0.0490 
Genus Reject Statistic raw pvalue 
Prevotella False 4.5167 0.0370 
[Eubacterium] xylanophilum group False 5.2780 0.0390 
Erysipelotrichaceae UCG-003 False 4.5916 0.0270 
MannWhitney- Feces       
Genus Reject Statistic raw pvalue 
Barnesiella False 196.0 0.0450 
Flavonifractor False 195.5 0.0500 
Veillonella False 197.5 0.0130 
Escherichia-Shigella False 196.5 0.0370 
 
To identify E. coli within the results, new reference database was used as a classifier. By using 
HOMD (Human oral microbiome database) newest version, new classifier was built and an earlier 
family-level group Enterobacteriacea was identified to be E. coli. However, the weakness of this 
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reference database was a much lower level of identification. Only 209 taxa were identified. Same 
tests were done as earlier in the QIIME2- environment, but some differences earlier identified were 
lost, and phylum level statistics was different by poorer identification levels.  
ASV-based differential abundance test was done in R-platform using Wilcoxon rank sum test 
which showed some differences, but most of them were not classified to taxa and none reached level 
of significance after FDR correction. Table VIII consist results for differential abundance test 
classified with SILVA reference database which identified taxas more specific. Table VIII Urine n. 
2 was classified to be genus Megasphaera member with HOMD reference database. 
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Figure 11 The relative abundance of taxa in urine samples after deployment of 80 % compliance limit. Used reference 
data Silva. Krona plots shows relative abundances at different taxonomic levels, from the center ring outward, lowest to 
highest identified taxonomic level is listed. When the highest identified taxonomic level is reached, outer ring contains 
lower taxonomic levels. Plots: A=Control, B= CLJ. 
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Figure 12 The relative abundance of taxa in feces samples after deployment of 80 % compliance limit. Used reference 
data Silva. Krona plots shows relative abundances at different taxonomic levels, from the center ring outward, lowest to 
highest identified taxonomic level is listed. When the highest identified taxonomic level is reached, outer ring contains 
lower taxonomic levels. Plots: A=Control, B= CLJ. 
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Table VIII ASV-based differential abundance test results           
 
SILVA- Urine           
 ASV p_value BH_FDR Kingdom Phylum Class Order Family Genus Species 
1 X8192e85fe5597e456b80adf23c6f855a 0.0204 0.3111 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
2 fd40c2bafd3d2210e7eacb0ed6c6f9a0 0.0204 0.3111 k__Bacteria p__Firmicutes c__Clostridia o__Clostridiales k__Bacteria p__Firmicutes c__Clostridia 
3 X6321b1f518746de382217f61a70874cb 0.0204 0.3111 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
4 X174a44be84eb24b6fd6aade8d1d7ad7a 0.0346 0.3111 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
5 X77034556117fd9ae9546fdabcaa458b4 0.0441 0.3111 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
SILVA- Feces           
 ASV p_value BH_FDR Kingdom Phylum Class Order Family Genus Species 
1 cba56d7b61d990145e0a6f42c072eec6 0.0127 0.9677 k__Bacteria p__Firmicutes c__Clostridia o__Clostridiales f__Ruminococcaceae g__Oscillospira s__ 
2 X75851d70210b9cfcaa48f6f69f33e1d6 0.0162 0.9677 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
3 X62f9258d944807cf94b3c9bfc19071d1 0.0237 0.9677 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
4 X45730ee0adc0dc5f26f0a605ac7bc14a 0.0255 0.9677 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
5 X4b29c8321281c949ef15f8072fcac607 0.0365 0.9677 <NA> <NA> <NA> <NA> <NA> <NA> <NA> 
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Figure 13 The relative abundance of taxa in urine samples after deployment of 80 % compliance limit. Used reference data HOMD. Krona plots shows relative abundances at different taxonomic 
levels, from the center ring outward, lowest to highest identified taxonomic level is listed. When the highest identified taxonomic level is reached, outer ring contains lower taxonomic levels. Plots: 
A=Control, B= CLJ. 
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Figure 14 The relative abundance of taxa in feces samples after deployment of 80 % compliance limit. Used reference data HOMD. Krona plots shows relative abundances at different taxonomic 
levels, from the center ring outward, lowest to highest identified taxonomic level is listed. When the highest identified taxonomic level is reached, outer ring contains lower taxonomic levels. Plots: 
A=Control, B= CLJ. 
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4.7. Abundance of specific urinary tract causing bacteria 
 
The heat tree analysis (Figure 10) and Krona plots (Figures 11-12) had already indicated differences 
in the Proteobacteria phylum between CLJ and control groups. Therefore, the abundance of bacterial 
pathogens typically connected with UTI: E. coli, Klebsiella spp., Pseudomonas aeruginosa, 
Enterococcus spp., Proteus spp., Enterobacter faecalis, Staphylococcus saprophyticus, 
Streptococcus agalactiae and Acinobacter were searched for from taxonomic data done with Silva -, 
Greengenes - and HOMD- reference databases. From those, E. coli and S. agalactiae and at genus 
level Enterococcus, Pseudomonas and Staphylococcus were identified by using HOMD- reference 
database.  
After deployment of 80 % compliance limit, the three months urine and feces data were used to 
build boxplots that show relative abundances of identified taxa (Figure 15). S. agalactiae was 
identified only in CLJ group urine samples. 
 
Figure 15 UTI connected pathogens relative abundance. A= E. coli, B= Staphylococcus & C=Enterococcus 
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Heatmap was used to visualize differences in abundance of UTI-related E. coli, Streptococcus, 
Enterococcus, Pseudomonas and Staphylococcus strains in urine and feces samples of patients in both 
treatment groups. Results in Figure 16 show that CLJ group patients have less E. coli strains in feces 
and urine samples than those in control group. There are also more other UTI connected bacterial 
strains, such as Enterococcus, in control group feces and urine samples than in CLJ group (Figure 
17). 
Alpha and Beta diversity was measured from data limited with UTI related ASVs. UTI related 
ASVs in feces samples was not normal distributed and in urine samples was normal distributed. Alpha 
diversity measures are shown in Figure 16. There were no significant differences in urine or feces 
samples in Alpha or Beta diversity. 
 
Figure 16 Alpha diversity metrics. Each measure is listed above each plot, and x-axel contains groups. Groups are divided by treatment, 
sample material and collection time in months. Last two are shown also as a color code: Turquoise indicates urine samples and red 
indicates 3 months feces samples.Y-axel  contains abundance metrics values. 
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Figure 17 Heatmap shows differences between sample material in patients at different treatment groups. Darker color 
indicates higher relative abundance. A= Control; B=CLJ. 
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5. Discussion 
 
5.1. Microbiome sequencing and analysis 
 
 
The aim of this research was to study effect of Cranberry-Lingonberry juice consumption on gut and 
urinary tract microbiome. The microbiome was analyzed by sequencing the V1-V8 variable regions 
of the ribosomal 16S RNA gene. The 16S ribosomal RNA barcodes based on V1-V8 regions have 
produced good results in earlier research (Chakravorty, 2007). Those have been successfully used to 
identify many bacterial species from small extracted amount of genetic material.  
Healthy gut microbiome composition varies between sex, age groups and even between 
individuals, but most dominant bacterial phyla are often the same. Typically, Firmicutes and 
Bacteroidetes represent 90 % of gut microbiome. Actinobacteria, Proteobacteria, Fusobacteria and 
Verrucomicrobia are also common to gut microbiome. In different conditions and under specific diet, 
those ratios can change (Huttenhower et al., 2012). The biggest problem in my study was finding the 
best alignment reference database so that the required taxa could be identified. Silva, Greengenes and 
HOMD have their pros and cons. Silva and Greengenes identified much more ASVs, but UTI related 
bacteria identification was poor. HOMD identified UTI related bacteria but had overall poor 
identification level. 
For alpha and beta diversity differences, the null hypothesis remained valid, and they were in 
many ways similar between groups. According to our results, this is good because patients involved 
in the research were the same aged children with a similar background. If something significant had 
been discovered, reason would have been something more than just CLJ-effect (Huttenhower et al., 
2012; Quinn et al., 2018). However, there were differences in relative abundances at species, phylum 
and family levels between treatments, which may serve as a basis for deeper research. 
 
5.2. Microbiome composition in cranberry-lingonberry consumption group and control group 
 
Biggest difference in this study was observed between sample materials (feces or urine). This was 
expected, as according to current knowledge our body has different microbial composition between 
different body parts. Urine samples indicate urinary tract area and feces samples gut environment 
(Huttenhower et al., 2012).  
In most of the samples, Bacteroidetes and Firmicutes dominated the microbiome. Other studies 
have shown that age and body mass index (BMI) can affect the Bacteroidetes and Firmicutes ratio 
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(Mariat et al., 2009; Koliada et al., 2017). The effect of antibiotics on Bacteroidetes/Firmicutes ratio 
has also been studied, where the antibiotic treatment increased the ratio between the two phyla 
(Dubourg, et al., 2013).  Proteobacteria relative abundance also changed between samples regardless 
of treatment in this study. Typically, healthy individuals have low abundance of Proteobacteria, and 
disease state correlates with its relative abundance (Shin et al., 2015). 
The cranberry-lingonberry juice (CLJ) had no such effect on relative abundance of gut 
microbiome as has been shown earlier on red wine polyphenols, increase in abundance of the phyla 
Proteobacteria, Actinobacteria, Fusobacteria, Firmicutes, and Bacteroidetes (Queipo-Ortuño et al., 
2012). There were differences between samples, but cranberry-lingonberry juice consumption was 
not clearly causing an increasing trend in those phyla. However, in our randomized trial, there were 
77 children, and in Queipo-Ortuño et al. (2018) randomized trial, there was only ten male participants, 
which could explain the differences. Also, the time period between trials was different. In our study 
samples were collected in one-year period, their study period was only 20 days. Our experimental 
setup allowed also other sources of polyphenols for the children. Therefore, our research data cannot 
be regarded to show polyphenol overall effect on gut microbiome at phylum level. As has been 
shown, polyphenols include a wide variety of compounds, of which most have effect on microbiomes 
at genus and species level. 
 
5.2.1. Urinary tract microbiome 
 
Heat tree shows that with most species, the log2 ratio between treatments was near zero, but every 
treatment group also contained some extremes. CLJ group urine samples had higher abundance, at 
order-level, Clostridiales and at class-level Bacteroidia. Control group contained more Firmicutes 
and Proteobacteria at phylum level. Many UTI causing pathogens belong to Proteobacteria, so this 
finding might indicate that CLJ has some effect to bacterial adhesion in urinary tract (Behzadi et. all, 
2010; Garout et al. ,2015).  
After deployment of 80 % compliance limit results confirmed the finding, although taxa- or ASV-
based differential abundance tests after FDR correction did not produce statistically significant 
differences. Urine krona plot shows that there are 7 % less Proteobacteria and 5 % less E. coli in CLJ 
group than in control group. The relative abundance of E. coli varies a lot between urine samples 
regardless of the treatment, i.e. there are ASVs for which relative abundance is less than 0.001 and 
others for which relative abundance is over 0.9. Typically, UTI and other illnesses cause E. coli to 
peak in urine and fecal samples (Garout et al., 2015). E. coli peak in urine samples could indicate that 
patients still has UTI. E. coli relative abundance median for urine samples is much lower in CLJ 
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group. Also, Kruskal Wallis test showed that phylum Proteobacteria difference was significant before 
FDR-correction. Regardless of losing significance after FDR correction, the results support the 
hypothesis that CLJ decreases amount of E. coli in urinary tract microbiota and affects against 
bacterial adhesion (Sobota et al. 1984; Zafriri et al., 1989; Raz et al., 2004; Kylli et al. 2011; Tapiainen 
et al., 2012; Kline et. al., 2016; Wojnicz, 2016; Paalanne et al., 2018).  
Interesting finding was that Firmicutes relative abundance was lower in control group (< 11 %) 
with deployment of 80 % compliance limit than without limitation. Heat tree- plot showed reverse 
results. Firmicutes and Bacteroidetes are typically the most dominant phylas in the human microbiota 
(Huttenhower et al., 2012). Relative abundance plot also showed that there are relative huge 
differences in samples regardless of the treatment.  
Even so, further analysis using HOMD- alignment database showed interesting results although 
differential abundance test did not show those to be significant. CLJ group contained more genus 
Lactobacillus members. There was 9 % Lactobacillus out of total bacteria. In control group the 
Lactobacillus relative abundance in urinary tract microbiome was minimal. This bacterial genus is 
typical to normal urinary tract microbiome (Hilt et al., 2014). There is also evidence that berries 
flavan-3-ols favor Lactobacillus (Cardona et al., 2016). Members of phylum Firmicutes could be 
colonizing the free space or the difference could be caused by another factor. More research should 
be done according to these findings. 
Krona plot of urine three months samples also showed 6 % difference in genus Staphylococcus 
between CLJ- and control-treatments. CLJ group relative abundance was lower, but boxplot showed 
that median in groups was nearly same. Also, the differences were not statistically different in taxa 
or ASV based tests. Heatmap shows that different members or strains of genus Staphylococcus are 
found in patients of different treatment groups. Interesting would be to find out which of those are 
pathogenic to human. It has been shown that Staphylococcus causes UTI and berry extracts can inhibit 
it (Imirzalioglu et al, 2008; Puupponen-Pimiä et al., 2005). Although, genus Staphylococcus members 
are part of healthy urinary tract microbiome (Hilt et al., 2014). 
Mann Whitney test results showed that the genus Finegoldia had significantly differential 
abundance between treatments in urine samples, but there was no available literature about its 
connection to UTI or cranberry and lingonberry polyphenols. Also, there were significant differences 
in genera Fastidiosipila and Negativicoccus before BH-FDR correction. Even so, in literature those 
genera have no any clear connection to UTI or polyphenols. 
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5.2.2. Gut microbiome 
 
Three months feces samples had significant differences in phylum Cyanobacteria. Closer look 
showed that the identified phylum included two classes, chloroplast and 4C0d-2. Of those, chloroplast 
(cp) was more abundant in CLJ group and 4C0d-2 in control group. Even so, relative amount of 
phylum Cyanobacteria was under 0.3 % in both treatment groups and there is no literature about 
connections to UTI. Still, interesting is that urine from CLJ group contained seemingly more 
chloroplast than control group. Berries cells include chloroplasts, and the cpDNA might be present 
in berry juice, so those can be originated from CLJ.  
There was also significant difference in genus Escheria-Shigella before BH-FDR correction. By 
Krona plot, genus was identified to contain only E. coli members. In CLJ group with deployment of 
80 % compliance limit E. coli relative abundance was 0.3 % and in control group 0.5 %. This finding 
could indicate that CLJ has effect on gut microbiome and possible UTI related pathogen strains 
(Paalanne et al., 2018). 
For many biochemical compounds, microbial metabolism is needed before their antioxidant 
properties can be utilized in the human body (Cassidy & Minihane, 2016; Chen et al., 2014). From 
our data such bacteria, Eggerthella lenta and Coprococcus eutactus were identified. E. lenta is 
member of phylum Actinobacteria and can catalyze the dihydroxylation of flavonoids in human 
gut (Braune & Blaut, 2016). Its relative abundance after deployment of 80 % compliance limit in CLJ 
group feces samples in three months timepoint was 0.09 % and in control group 0.04 %. This could 
suggest abundance rising for bacteria that can catabolize cranberry polyphenols, however the 
difference was not significant. C. eutactus can produce butyrate metabolite from polysaccharides in 
gut (Wang, et al., 2019). Other taxa earlier connected with polyphenol effects on gut microbiome 
(Cardona et al., 2013; Braune & Blaut, 2016) were not identified. Even so, polyphenols are shown to 
affect microbiome in other studies, so these results should be taken under closer examination in the 
future (Cardona et al., 2013). 
Akkermansia and Faecalibacterium were also identified in three months fecal and urine data 
alignment by Silva reference database. Abundance rise of both genera has earlier been shown to be 
connected to lingonberry polyphenols (Heyman-Lindén et al., 2016). There were not significant 
differences between treatments in this study. CLJ group contained genus Akkermansia in 0.8 % of 
total bacterial abundance in feces samples and 0.07 % in urine samples. Abundance of Akkermansia 
was much less in control group, as fecal samples contained 0.4 % and urine samples 0.02 % of 
Akkermansia out of total bacterial abundance. Although the results were not significant, this suggests 
that CLJ polyphenols might change gut microbiome. 
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5.2.3. PACs longtime effect to gut microbiome 
  
In three-month fecal treatment group, highly different abundant species were found in Bacteroidales 
and Clostridiales according to heat tree-plot. Both orders contained members that were more common 
under both treatments. Earlier studies have shown that polyphenol-rich diet caused ecological shifts 
in gut microbiome of pigs, and Lachnospiraceae- and Ruminococcaccea-families were ones with 
increased abundances. On the other hand, that study used PACs from grape seeds, which contain 
more B-type PACs (Choy, Y. et al, 2014) compared to the A-type PACs of cranberry and lingonberry.   
Krona plots done using Silva alignment database were used to get closer look for differences. After 
deployment of 80 % compliance limit, Lachnospiraceae-family members were more abundant in CLJ 
group. There was 5 % difference between treatment groups in bacterial relative abundances. ASV 
based differential abundance test also showed that family Ruminococcaccea member, genus 
Oscillospira, reached level of significance before FDR correction in three months sample group with 
deployment of 80 % compliance limit. Connection of Oscillospira to polyphenols has not been 
identified. 
Lachnospiraceae and Ruminococcacceae -family abundance increased across time in fecal 
samples under CLJ-treatment.  According to the study design, the CLJ effect should be visible from 
three months samples on, so this finding might be connected to CLJ effect on gut microbiome even 
though the result was not statistically significant (Choy et al, 2014).  
Overall the heat tree analysis results supported hypothesis that CLJ could influence gut microbiome, 
because the species occurrence was different between treatment groups. There were ecological shifts 
in the order Clostridiales, and phyla Proteobacteria and Verrucomicrobia across time in the fecal 
samples. There were families and genera for which abundance under treatments changed across time. 
E.g. one Enterobacteriales member, for which the abundance was higher in CLJ group than in the 
control group in fecal samples of twelve-month timepoint, has higher abundance in control group in 
six-month timepoint. This is interesting, because many Enterobacteriales members, E. coli, Klebsiella 
sp., Proteus sp. and Enterobacter sp., are connected to UTI and typically related to urinary tract 
microbiome (Behzadi et. all, 2010; Garout et al. ,2015). There could also be other reasons for such 
fluxes besides treatment, such as natural variation and study design (Huttenhower et al., 2012). To 
get statistically significant results, the differences could be further analyzed in six - and twelve months 
feces samples with deployment of 80 % compliance limit and by using HOMD- alignment database. 
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5.3.  Gut – and urinary tract microbiome connection 
 
To examine the hypothesis that UTI-causing pathogenic strains enter urethra from gut microbiome, 
which is potentially affected by CLJ, heatmaps on potentially UTI-causing strains were built and 
compared between patients’ urine and gut samples. Heatmap showed that there mainly are different 
bacterial strains of E. coli in research patients’ urine and feces samples. However, some strains were 
only found from control group feces and urine samples. This finding shows that PACs might affect 
bacterial conditions and favor specific E. coli strains over others. Many earlier studies show that 
cranberry proanthocyanidins may inhibit the adhesion of type I and P-fimbriated uropathogens (Gupta 
K et al., 2007; Lavigne et al., 2008; Zafriri et al., 1989). Members in the family Enterobacteriaceae 
typically have such an adhesion mechanism, for example, E. coli. E. coli strains are also a common 
part of normal microbiome, typically found in feces. Therefore, differentiating a pathogenic version 
from “normal inhabitants” is hard. More studies should be done to find out which of the strains are 
uropathogenic. 
Differences were also found among strains of Streptococcus and Staphylococcus genera. Both 
consist UTI related pathogen strains and Streptococcus agalactiae, which is related to UTI, was 
identified. Interestingly, it was found only in CLJ group urine samples.  
Genus Streptococcus was less abundant in CLJ group (0.3 %) than in control group (0.7 %) feces 
samples, and in urine samples, the situation was opposite. In CLJ group the abundance was 2 % and 
in control group 0.2 %. On the other hand, Staphylococcus was more abundant in CLJ group (0.08 
%) than in control group (0.02 %) feces samples, but in urine samples, the situation was opposite. In 
CLJ group the abundance was 1 % and in control group 6 %. Even though differential abundances 
between CLJ and control group in these genera were not statistically significant, differences could be 
caused by PACs effect to bacterial adhesion.  
There was also a couple of patients in control group that had members of Pseudomonas genus in 
their gut and urinary tract microbiota. Also, Enterococcus strains were found in patients’ samples. 
An earlier study has shown that cranberry extract inhibits Enterococcus faecalis growth and 
enzymatic activities and limits biofilm formation in vitro (Wojnicz et al., 2016). Our results showed 
that there were a couple of patients in control groups containing relative high abundance of genus 
Enterococcus strains, but in other patients its abundance was limited. Therefore, there could be some 
connection between treatment and abundance of this bacterium.  
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6. Conclusions and outlook 
 
There were significant differences in microbial abundance at phylum, genera and even ASVs level 
between CLJ and control group treatments, and some findings reached level of significance, but lost 
it after BH-FDR correction. In urine samples with deployment of 80 % compliance limit genus 
Finegoldia was differentially abundant between CLJ and control group. However, there was not 
literature about its connection to UTI or polyphenols. Difference in phylum Proteobacteria reached 
level of significant before BH-FDR correction. As our hypothesis is that CLJ PACs might affect UTI 
related pathogen adhesion in urinary tract, this finding is the most important. Many UTI-related 
pathogens including E. coli belong to phylum Proteobacteria. In feces with deployment of 80 % 
compliance limit there was significantly differentially abundant taxa before BH-FDR. Most important 
was Escheria-Shigella which was later identified to present E. coli at species level. This finding 
indicates that CLJ might affect UTI related bacteria in gut environment. 
After application of compliance limit relative abundance results became more rational although 
Alpha and Beta diversity analysis results had no change. The most interesting, although statistically 
non-significant, finding was that there were clearer differences in the relative abundance levels of E. 
coli in the urine samples after application of compliance limit. With compliance limit applied, the 
relative abundance median of E. coli in samples was much lower in CLJ treatment group samples. 
The relative abundances of E. coli were also lower, potentially indicating that CLJ has an effect on 
bacterial adhesion.  
Abundance of another UTI causing genus Staphylococcus, which belongs to Firmicutes phylum, 
was also lower in the CLJ group, even though levels of Firmicutes overall were higher in the CLJ 
group. On the other hand, control group samples contained such abundances of Enterococcus and 
Pseudomonas genus that were not identified in the CLJ group samples. These results could also 
suggest that cranberry-lingonberry juice consumption changes gut and urine microbiota, specifically 
on potentially pathogenic strains, and may through these mechanisms affect occurrence of UTI. More 
accurate reference alignment data might help to identify taxa at species level and show more 
interesting differences.  
Many factors affect gut microbiome, and many factors are also connected with effects of 
polyphenols on the body and on the microbiome. E.g. UTI is more common in women than in men, 
and E. coli is more common UTI causing organism in boys than in girls. Therefore, there can be 
differences between boys and girls on their urinary tract inhabitants and relative abundances of 
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pathogens under various treatments. Furthermore, gram-positive UTI causing bacteria are common 
in patients with other UTI risk factors (Kline & Lewis, 2016). Medication and diet might also 
influence the results on gut microbiome (Chen et al, 2014; Choy et al., 2014; Mariat et al., 2009; 
Koliada et al., 2017).  
These factors should be mapped out in participants of the research. Information about past 
antibiotics uses, dietary and medical history could be utilized in statistical analysis to provide more 
information about CLJ effect on gut microbiomes at Phylum- level ratios. Wider hospital metadata 
information might be good for subgroup studies.  
Medical history of the patients recruited for this study would enable comparisons of groups shared 
by similar UTI history. Urine samples of patients with similar UTI history under CLJ treatment should 
contain similar uropathogens. It would be interesting to study more which microbial groups that are 
tolerant to CLJ polyphenols utilize and colonize the space freed by sensitive species. Other studies 
have shown that the combination of probiotics and AC-PACs give best results against UTI (Polewski, 
2016). Our findings support those. Could a healthy diet itself drive ecological shift towards higher 
mutualism in gut microbiome without added medication?  
Studies have shown that fecal and urine samples typically contain colonic degradation products 
of major PACs (Cassidy & Minihane, 2016). PAC and other phenolic metabolites concentration 
should be measured in samples. Earlier study done with animal models has shown that there might 
be connection between fecal iron and food-borne pathogenic bacteria in the gut. Iron deficiency 
reduces pathogenic bacterial strains in the gut (Kortman et al., 2015). Paalanne et al. (2018) studied 
fecal iron and lactoferrin concentrations in research where UTI patient’s microbiome was compared 
to control group microbiome. Results were not statistically significant and further research would be 
needed (Paalanne et al., 2018). Chemical information combined with microbial data from samples 
could give more information about CLJ long-time effects on gut and urinary tract microbiome and 
microbial colonization. A-type PACs have also reduced Candida albicans adhesion properties, 
therefore, fungal analysis could also be done (Rauf et al., 2019). 
In the future, when more information about microbial metabolism is gathered, this data could be 
used for analyzing the role of bacteria in the decomposition of polyphenols. Work is still in progress, 
and information from in vitro studies cannot be fully utilized until more in vivo studies have been 
done. And more in vitro studies are needed for understanding what takes place in the microbiome of 
a higher organism, so dialogue between these research fields shall continue  
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Appendix 
Electrophoresis pictures 
 
  
 
 
 
 
 
 
 
28.1.2019 Ladder, 2 x neg., empty and samples. 
- Sample 152 is last one from left to right 
29.1.2019 Ladder, 2 x neg., empty and samples. 
- Sample 136 6th column 
30.1.2019 Ladder, 2 x neg., empty and samples. 
- Samples: 50 11th column, 175 18th column, 215 5th column 
31.1.2019 
- Ladder, 2 x neg. , empty and samples 
- Samples: 186 last column, 194 16th column, 191 9th column 
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15.2.Ladder, 4x neg.control, 2 x empty and samples. From the list contamined neg. 
controls and empty bands are deleted 
Samples: 85 4 10 23 210 96 36 2 39 17 49 60 144 66 7 38 26 34 200 92 6 82  
- 19.2.2019 Ladder, 4 neg.control, 2 x empty and samples. From the list contamined neg. controls 
and empty bands are deleted 
Samples: 86.2 70 55 44 177 205 91 5 3 14 32.2 189 96.2 72 31 89 13 33.2 206 184 78 80 88 176  
11.2.2019 Ladder, 3 x neg. and samples 
- Samples: 7 19th column, 38 14th column 
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25.2.2019 Ladder, 4 neg.control, 2 x empty and samples. From the list contamined neg. controls 
and empty bands are deleted 
Samples:46 51 57 53 138 199 15 9 48 11 54 193 28 90 95 8 47 20 203 207 83 81 140 201  
1.4.2019 - First two after ladder are neg.controls. After that samples in list order, empty 
bands aren't in the list. Two last samples were in another gel because lack of space. 
74 128 125 110 114 156 129 63 74.2 101  
103 155 98 139 121 106 113 126 158 153 99 157  
2.4.2019 Last two are from 1.4.2019 PCR, something did go 
wrong with this PCR and i didn't get anything 
Samples: 100.2 117  
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2.4.2019 -After ladder three neg. controls, empty and then samples in the list order 
Samples: 168 190 35 119 149 137 212 165 118 97.2  
178 41 109 75 37 20 86 102 92 120 9 108 105 18 204.2 69.2 180 172  
3.4.2019 - After ladder three neg. controls, empty and then samples/primers in list order 
Samples: 93 79 76 168 45 77 150 24 94 58  
67 127 111 112.2 198 211 183 213 19..1 214 36 122 42.2 181 163 167 137  
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5.4.2019 Ladder, empty (primer run out), 3 x neg, 2 x empty and samples (24) 
Samples: 208 12 169 146 22 165 141 151 192 21 166 204 164 
 182 179 40 171 145 116 161 197 147 170 43 148 
9.4.2019 Ladder, 2 x neg, 2 x empty and samples (10) 
Samples:159 160 162 173 174 187 188 195 209 107  
10.4.2019 Ladder, 2 x neg, 2 x empty and samples (24) 
Samples: 1 16 25 27 29 30 32 33 42 52  
59 62 64 68 71 73 84 87 115 123 124 142 143 154  
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28.6 Ladder, 3 x neg.control, 2 x empty, samples 
Samples: 4 210 36 7 215 172(DIDN'T GIVE BAND) 191  
 
64 
 
Metadata 
 
#SampleID sample fPrimer barcode-sequence LinkerPrimerSequence Research
 TreatmentGroup Description DaysSinceExperimentStart SampleMaterial TotalSamples
 TreatmentGroup2 FecesTotal TreatMatTime TreatGroup 
1 1 132 GACACATTC CAGCMGCCGCGGTAATWC 39 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
2 2 22 CACACTATC CAGCMGCCGCGGTAATWC 56 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
3 3 45 TATATCACT CAGCMGCCGCGGTAATWC 55 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
4 4 28 CACGTCGTC CAGCMGCCGCGGTAATWC 31 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
5 5 44 CATATCATC CAGCMGCCGCGGTAATWC 10 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
6 6 5 CTATATGTC CAGCMGCCGCGGTAATWC 1 1
 Näyte 3 kk F-karpu 90 Feces 2 1 2
 T1_Feces_3 First 
7 7 42 TATGCTGCT CAGCMGCCGCGGTAATWC 54 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
8 8 81 CCGTACATC CAGCMGCCGCGGTAATWC 20 1
 Näyte 6 kk F-karpu 180 Feces 2 1 2
 T1_Feces_6 First 
9 9 205 TAACTCTCT CAGCMGCCGCGGTAATWC 6 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
10 10 27 CGCATCACT CAGCMGCCGCGGTAATWC 15 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
11 11 74 GACGTGCTC CAGCMGCCGCGGTAATWC 20 1
 Näyte 3 kk F-karpu 90 Feces 2 1 2
 T1_Feces_3 First 
12 12 9 ACATGATCT CAGCMGCCGCGGTAATWC 10 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
13 13 55 CAATCTCTC CAGCMGCCGCGGTAATWC 18 2
 Näyte 3 kk F-karpu 90 Feces 1 2 1
 T2_Feces_3 Second 
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14 14 47 ACTCTCTCT CAGCMGCCGCGGTAATWC 24 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
15 15 70 TACTGTAGG CAGCMGCCGCGGTAATWC 11 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
16 16 103 ATTAGAGTC CAGCMGCCGCGGTAATWC 28 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
17 17 20 AGCGCACTC CAGCMGCCGCGGTAATWC 41 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
18 18 208 CAGAGAGTC CAGCMGCCGCGGTAATWC 14 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
19 19 236 CTGCACGCT CAGCMGCCGCGGTAATWC 51 1
 Näyte 3 kk F-karpu 90 Feces 2 1 2
 T1_Feces_3 First 
20 20 200 TGCATCATC CAGCMGCCGCGGTAATWC 26 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
21 21 114 TCACAGCAA CAGCMGCCGCGGTAATWC 3 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
22 22 108 CGTGTCGCT CAGCMGCCGCGGTAATWC 7 1
 Näyte 3 kk F-karpu 90 Feces 2 1 2
 T1_Feces_3 First 
23 23 26 TACTGATCT CAGCMGCCGCGGTAATWC 11 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
24 24 225 ACATGTAGG CAGCMGCCGCGGTAATWC 22 1
 Näyte 3 kk F-karpu 90 Feces 2 1 2
 T1_Feces_3 First 
25 25 102 TATCGACCT CAGCMGCCGCGGTAATWC 1 1
 Näyte 6 kk F-karpu 180 Feces 2 1 2
 T1_Feces_6 First 
26 26 12 TCATGTACT CAGCMGCCGCGGTAATWC 14 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
27 27 97 TGTCATAGG CAGCMGCCGCGGTAATWC 43 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
28 28 78 GATGCACTC CAGCMGCCGCGGTAATWC 3 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
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29 29 90 TCGATACCT CAGCMGCCGCGGTAATWC 12 2
 Näyte 3 kk F-karpu 90 Feces 2 2 2
 T2_Feces_3 Second 
30 30 89 TTGTGTATC CAGCMGCCGCGGTAATWC 28 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
31 31 52 ATAGCACGG CAGCMGCCGCGGTAATWC 6 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
34 34 11 TCATGCGTC CAGCMGCCGCGGTAATWC 43 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
35 35 185 CATATGTGG CAGCMGCCGCGGTAATWC 7 1
 Näyte 12 kk F-karpu 360 Feces 2 1 2
 T1_Feces_12 First 
36 36 238 GCGCGGTCT CAGCMGCCGCGGTAATWC 48 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
37 37 199 ACAACTACT CAGCMGCCGCGGTAATWC 38 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
38 38 98 AGTACATTC CAGCMGCCGCGGTAATWC 11 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
39 39 21 AGCGCGTCT CAGCMGCCGCGGTAATWC 32 2
 Näyte 3 kk F-karpu 90 Feces 1 2 1
 T2_Feces_3 Second 
40 40 120 GCCGAGATC CAGCMGCCGCGGTAATWC 35 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
41 41 196 GTAGCCATC CAGCMGCCGCGGTAATWC 40 2
 Näyte 3 kk F-karpu 90 Feces 1 2 1
 T2_Feces_3 Second 
43 43 137 GCCAGAGTC CAGCMGCCGCGGTAATWC 41 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
44 44 39 AGTCATATC CAGCMGCCGCGGTAATWC 37 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
45 45 221 GTACGACCT CAGCMGCCGCGGTAATWC 3 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
46 46 60 ACAGTATGG CAGCMGCCGCGGTAATWC 15 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
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47 47 83 TTGCATACT CAGCMGCCGCGGTAATWC 35 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
48 48 73 GACGTATCT CAGCMGCCGCGGTAATWC 39 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
49 49 18 CGCTAGTCT CAGCMGCCGCGGTAATWC 14 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
50 50 62 CGCTACAGG CAGCMGCCGCGGTAATWC 38 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
51 51 61 ACAGTTATC CAGCMGCCGCGGTAATWC 31 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
52 52 46 TGTGTCGTC CAGCMGCCGCGGTAATWC 28 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
53 53 66 ATCTCCTCT CAGCMGCCGCGGTAATWC 22 1
 Näyte 6 kk F-karpu 180 Feces 2 1 2
 T1_Feces_6 First 
54 54 75 GTGACTACT CAGCMGCCGCGGTAATWC 37 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
55 55 38 TGTCAGCTC CAGCMGCCGCGGTAATWC 15 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
57 57 65 AACACATCT CAGCMGCCGCGGTAATWC 10 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
58 58 227 CGCATTGTC CAGCMGCCGCGGTAATWC 33 2
 Näyte 3 kk F-karpu 90 Feces 1 2 1
 T2_Feces_3 Second 
59 59 69 AACTGTATC CAGCMGCCGCGGTAATWC 6 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
60 60 17 AGCTACACT CAGCMGCCGCGGTAATWC 25 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
62 62 87 ACGCGACCT CAGCMGCCGCGGTAATWC 50 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
63 63 156 CAGGAGATC CAGCMGCCGCGGTAATWC 50 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
 
68 
 
64 64 100 CATGCCACT CAGCMGCCGCGGTAATWC 31 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
66 66 15 GCAGTCGTC CAGCMGCCGCGGTAATWC 7 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
67 67 228 TAGAGGATC CAGCMGCCGCGGTAATWC 12 2
 Näyte 6 kk F-karpu 180 Feces 2 2 2
 T2_Feces_6 Second 
68 68 101 AGTACGCCT CAGCMGCCGCGGTAATWC 52 1
 Näyte 3 kk F-karpu 90 Feces 1 1 1
 T1_Feces_3 First 
70 70 35 ATGACTATC CAGCMGCCGCGGTAATWC 41 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
71 71 104 AATCGCACT CAGCMGCCGCGGTAATWC 74 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
72 72 51 GCACAGCTC CAGCMGCCGCGGTAATWC 73 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
73 73 105 AATCGTGTC CAGCMGCCGCGGTAATWC 71 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
75 75 198 GTAGCGTGG CAGCMGCCGCGGTAATWC 51 1
 Näyte 6 kk F-karpu 180 Feces 2 1 2
 T1_Feces_6 First 
76 76 219 AGACCGACT CAGCMGCCGCGGTAATWC 59 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
77 77 222 TGAAGAGTC CAGCMGCCGCGGTAATWC 68 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
78 78 30 TCGTACACT CAGCMGCCGCGGTAATWC 67 2
 Näyte 3 kk F-karpu 90 Feces 1 2 1
 T2_Feces_3 Second 
79 79 218 TGAGAGATC CAGCMGCCGCGGTAATWC 62 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
80 80 31 ATGCAGCTC CAGCMGCCGCGGTAATWC 62 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
81 81 92 TCGATGTTC CAGCMGCCGCGGTAATWC 48 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
 
69 
 
82 82 4 TCACATATC CAGCMGCCGCGGTAATWC 50 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
83 83 91 CTGGTATCT CAGCMGCCGCGGTAATWC 56 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
84 84 106 TCTCTAACT CAGCMGCCGCGGTAATWC 54 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
85 85 29 TACGTCGCT CAGCMGCCGCGGTAATWC 64 1
 Näyte 3 kk F-karpu 90 Feces 2 1 1
 T1_Feces_3 First 
87 87 112 GCACACGAA CAGCMGCCGCGGTAATWC 56 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
88 88 32 ACGTAGTCT CAGCMGCCGCGGTAATWC 54 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
89 89 53 AGACCAGTC CAGCMGCCGCGGTAATWC 37 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
90 90 79 GATGCGTCT CAGCMGCCGCGGTAATWC 43 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
91 91 43 AGTGTATCT CAGCMGCCGCGGTAATWC 50 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
92 92 203 ATAATCATC CAGCMGCCGCGGTAATWC 55 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
93 93 217 TCACACGCT CAGCMGCCGCGGTAATWC 59 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
94 94 226 AGATTAGCT CAGCMGCCGCGGTAATWC 35 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
95 95 80 TACGTTATC CAGCMGCCGCGGTAATWC 39 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
98 98 162 GAGAGCCTC CAGCMGCCGCGGTAATWC 59 1
 Näyte 3 kk U-karpu 90 Urine 3 1 3
 T1_Urine_3 First 
99 99 140 GACTGCGTC CAGCMGCCGCGGTAATWC 85 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
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101 101 158 CCGTATGCT CAGCMGCCGCGGTAATWC 87 2
 Näyte 3 kk U-karpu 90 Urine 1 2 1
 T2_Urine_3 Second 
102 102 202 TTACGTGTC CAGCMGCCGCGGTAATWC 79 2
 Näyte 3 kk U-karpu 90 Urine 3 2 3
 T2_Urine_3 Second 
103 103 160 TTGACATCT CAGCMGCCGCGGTAATWC 81 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
105 105 207 ACGTACAGG CAGCMGCCGCGGTAATWC 75 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
106 106 170 ACGATTGTC CAGCMGCCGCGGTAATWC 80 1
 Näyte 3 kk U-karpu 90 Urine 2 1 1
 T1_Urine_3 First 
107 107 190 TGAGAAGCT CAGCMGCCGCGGTAATWC 90 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
108 108 206 GCAGTTACT CAGCMGCCGCGGTAATWC 97 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
109 109 197 ATAGCCACT CAGCMGCCGCGGTAATWC 98 1
 Näyte 3 kk U-karpu 90 Urine 3 1 3
 T1_Urine_3 First 
110 110 151 CACGTTACT CAGCMGCCGCGGTAATWC 99 2
 Näyte 3 kk U-karpu 90 Urine 3 2 3
 T2_Urine_3 Second 
111 111 230 GCGATGTGG CAGCMGCCGCGGTAATWC 92 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
113 113 171 TATTAGTCT CAGCMGCCGCGGTAATWC 
 Unknown None Unknown Unknown Unknown Unknown
 Unknown  First 
114 114 152 TGCATTGCT CAGCMGCCGCGGTAATWC 95 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
115 115 107 AATATACTC CAGCMGCCGCGGTAATWC 68 1
 Näyte 3 kk U-karpu 90 Urine 3 1 3
 T1_Urine_3 First 
116 116 125 CTCAATCTC CAGCMGCCGCGGTAATWC 96 2
 Näyte 3 kk U-karpu 90 Urine 2 2 1
 T2_Urine_3 Second 
117 117 146 TACGTATGG CAGCMGCCGCGGTAATWC 
 Unknown None Unknown Unknown Unknown Unknown
 Unknown  First 
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118 118 191 GCACATAGG CAGCMGCCGCGGTAATWC 102 1
 Näyte 3 kk U-karpu 90 Urine 3 1 3
 T1_Urine_3 First 
119 119 186 CGTGTTATC CAGCMGCCGCGGTAATWC 106 2
 Näyte 3 kk U-karpu 90 Urine 1 2 1
 T2_Urine_3 Second 
120 120 204 GTAATCACT CAGCMGCCGCGGTAATWC 109 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
121 121 168 GTGGTCGCT CAGCMGCCGCGGTAATWC 104 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
122 122 239 TTGTGCGCT CAGCMGCCGCGGTAATWC 103 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
123 123 122 CACCAGCTC CAGCMGCCGCGGTAATWC 74 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
124 124 159 ATGACATGG CAGCMGCCGCGGTAATWC 73 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
125 125 150 TGCATGTGG CAGCMGCCGCGGTAATWC 71 2
 Näyte 3 kk U-karpu 90 Urine 3 2 3
 T2_Urine_3 Second 
126 126 172 TCTAATCTC CAGCMGCCGCGGTAATWC 76 2
 Näyte 3 kk U-karpu 90 Urine 3 2 3
 T2_Urine_3 Second 
127 127 229 ACGATCACT CAGCMGCCGCGGTAATWC 78 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
128 128 149 AGCATGTTC CAGCMGCCGCGGTAATWC 64 1
 Näyte 3 kk U-karpu 90 Urine 2 1 1
 T1_Urine_3 First 
129 129 155 TTGCACGTC CAGCMGCCGCGGTAATWC 65 2
 Näyte 3 kk U-karpu 90 Urine 4 2 4
 T2_Urine_3 Second 
136 136 2 CGAGAGACT CAGCMGCCGCGGTAATWC 109 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
137 137 216 GCTCTCTTC CAGCMGCCGCGGTAATWC 110 2
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
138 138 67 ACCAGAGCT CAGCMGCCGCGGTAATWC 95 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
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139 139 163 CAGAGGACT CAGCMGCCGCGGTAATWC 111 1
 Näyte 3 kk U-karpu 90 Urine 3 1 3
 T1_Urine_3 First 
140 140 94 TGTCAATCT CAGCMGCCGCGGTAATWC 111 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
141 141 110 CATATTGCT CAGCMGCCGCGGTAATWC 102 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
142 142 174 TATGCGTGG CAGCMGCCGCGGTAATWC 105 2
 Näyte 3 kk F-karpu 90 Feces 2 2 1
 T2_Feces_3 Second 
143 143 164 GTGTGTAGG CAGCMGCCGCGGTAATWC 102 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
144 144 16 TCAGTGCTC CAGCMGCCGCGGTAATWC 104 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
145 145 124 GACCATATC CAGCMGCCGCGGTAATWC 85 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
147 147 133 CACACATGG CAGCMGCCGCGGTAATWC 99 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
148 148 139 CACTGATTC CAGCMGCCGCGGTAATWC 91 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
149 149 187 TGTGTTACT CAGCMGCCGCGGTAATWC 98 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
150 150 223 CCATGCGCT CAGCMGCCGCGGTAATWC 103 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
151 151 111 GTATACAGG CAGCMGCCGCGGTAATWC 97 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
152 152 96 CGTCAGCCT CAGCMGCCGCGGTAATWC 82 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
153 153 178 AGTTGCGTC CAGCMGCCGCGGTAATWC 84 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
154 154 167 ATGGTCGTC CAGCMGCCGCGGTAATWC 95 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
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155 155 161 TTGACGCTC CAGCMGCCGCGGTAATWC 112 2
 Näyte 3 kk U-karpu 90 Urine 2 2 1
 T2_Urine_3 Second 
156 156 154 ATGCAATCT CAGCMGCCGCGGTAATWC 113 1
 Näyte 3 kk U-karpu 90 Urine 3 1 3
 T1_Urine_3 First 
157 157 143 GGCATACTC CAGCMGCCGCGGTAATWC 108 1
 Näyte 3 kk U-karpu 90 Urine 2 1 1
 T1_Urine_3 First 
158 158 176 CGTTGATCT CAGCMGCCGCGGTAATWC 108 1
 Näyte 3 kk F-karpu 90 Feces 2 1 1
 T1_Feces_3 First 
159 159 14 TCAGTATCT CAGCMGCCGCGGTAATWC 113 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
160 160 71 GACTGTACT CAGCMGCCGCGGTAATWC 103 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
161 161 241 GCGCGCAGG CAGCMGCCGCGGTAATWC 104 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
162 162 84 TCGGCACTC CAGCMGCCGCGGTAATWC 110 2
 Näyte 3 kk F-karpu 90 Feces 2 2 2
 T2_Feces_3 Second 
163 163 214 AGTCACGCT CAGCMGCCGCGGTAATWC 92 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
164 164 117 ATATAGTTC CAGCMGCCGCGGTAATWC 90 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
165 165 109 AATATGTCT CAGCMGCCGCGGTAATWC 103 1
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
166 166 115 ACACAGCCT CAGCMGCCGCGGTAATWC 97 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
167 167 215 ATTGAGATC CAGCMGCCGCGGTAATWC 109 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
168 168 220 GCAACTATC CAGCMGCCGCGGTAATWC 99 2
 Näyte 3 kk F-karpu 90 Feces 2 2 2
 T2_Feces_3 Second 
170 170 134 TACACCGTC CAGCMGCCGCGGTAATWC 104 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
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171 171 121 ACCGAGACT CAGCMGCCGCGGTAATWC 81 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
172 172 212 GAGTTAGCT CAGCMGCCGCGGTAATWC 92 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
173 173 23 TACACTACT CAGCMGCCGCGGTAATWC 96 2
 Näyte 3 kk F-karpu 90 Feces 2 2 1
 T2_Feces_3 Second 
174 174 13 CTACGTGCT CAGCMGCCGCGGTAATWC 84 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
175 175 63 TGCTAGTTC CAGCMGCCGCGGTAATWC 95 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
176 176 33 CTGCATATC CAGCMGCCGCGGTAATWC 90 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
177 177 40 TGTACTATC CAGCMGCCGCGGTAATWC 98 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
178 178 195 TTATATGCT CAGCMGCCGCGGTAATWC 97 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
179 179 119 CTCAACTCT CAGCMGCCGCGGTAATWC 75 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
180 180 211 CTGTGTACT CAGCMGCCGCGGTAATWC 78 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
181 181 213 CTGGTGCTC CAGCMGCCGCGGTAATWC 85 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
182 182 118 GACCACGCT CAGCMGCCGCGGTAATWC 73 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
183 183 234 TCTGGCTTC CAGCMGCCGCGGTAATWC 91 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
184 184 59 CCATGTATC CAGCMGCCGCGGTAATWC 82 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
185 185 128 CTCTCAATC CAGCMGCCGCGGTAATWC 92 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
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186 186 10 CTACGCATC CAGCMGCCGCGGTAATWC 90 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
187 187 88 GCGCGACTC CAGCMGCCGCGGTAATWC 65 2
 Näyte 12 kk F-karpu 360 Feces 4 2 4
 T2_Feces_12 Second 
188 188 7 ATAGCTGTC CAGCMGCCGCGGTAATWC 81 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
189 189 49 CGAGAAGTC CAGCMGCCGCGGTAATWC 85 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
190 190 184 TCTCTGGTC CAGCMGCCGCGGTAATWC 76 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
191 191 127 GGCTATGCT CAGCMGCCGCGGTAATWC 81 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
192 192 113 CCACACGTC CAGCMGCCGCGGTAATWC 74 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
193 193 76 GTGTGATCT CAGCMGCCGCGGTAATWC 74 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
194 194 99 TGTACATGG CAGCMGCCGCGGTAATWC 78 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
195 195 188 ACTCTTCTC CAGCMGCCGCGGTAATWC 75 1
 Näyte 6 kk F-karpu 180 Feces 4 1 4
 T1_Feces_6 First 
197 197 242 ATGACCGCT CAGCMGCCGCGGTAATWC 68 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
198 198 232 CATCGCAGG CAGCMGCCGCGGTAATWC 82 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
199 199 68 TACTGGCTC CAGCMGCCGCGGTAATWC 82 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
200 200 8 ATACGACTC CAGCMGCCGCGGTAATWC 65 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
201 201 95 TCTAACTCT CAGCMGCCGCGGTAATWC 80 1
 Näyte 3 kk F-karpu 90 Feces 2 1 1
 T1_Feces_3 First 
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203 203 85 CTGACATTC CAGCMGCCGCGGTAATWC 84 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
205 205 41 CGTACTACT CAGCMGCCGCGGTAATWC 78 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
206 206 58 TTACGCACT CAGCMGCCGCGGTAATWC 73 2
 Näyte 6 kk F-karpu 180 Feces 4 2 4
 T2_Feces_6 Second 
207 207 86 TGGTCTCTC CAGCMGCCGCGGTAATWC 71 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
208 208 6 CTAGCACTC CAGCMGCCGCGGTAATWC 75 1
 Näyte 3 kk F-karpu 90 Feces 4 1 4
 T1_Feces_3 First 
209 209 179 CATCGGTCT CAGCMGCCGCGGTAATWC 72 1
 Näyte 6 kk F-karpu 180 Feces 1 1 1
 T1_Feces_6 First 
210 210 25 TGCGCTGTC CAGCMGCCGCGGTAATWC 76 2
 Näyte 3 kk F-karpu 90 Feces 3 2 3
 T2_Feces_3 Second 
211 211 233 TATATACGG CAGCMGCCGCGGTAATWC 105 2
 Näyte 3 kk U-karpu 90 Urine 2 2 1
 T2_Urine_3 Second 
212 212 189 TATATTGTC CAGCMGCCGCGGTAATWC 113 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
213 213 235 CTGACGCCT CAGCMGCCGCGGTAATWC 109 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
214 214 237 CCGCGTGTC CAGCMGCCGCGGTAATWC 111 1
 Näyte 6 kk F-karpu 180 Feces 3 1 3
 T1_Feces_6 First 
215 215 36 TCGCGCATC CAGCMGCCGCGGTAATWC 112 2
 Näyte 6 kk F-karpu 180 Feces 2 2 1
 T2_Feces_6 Second 
100_2 100_2 144 GTCTCTCCT CAGCMGCCGCGGTAATWC 84 1
 Näyte 3 kk U-karpu 90 Urine 4 1 4
 T1_Urine_3 First 
112_2 112_2 231 CGTACCGTC CAGCMGCCGCGGTAATWC 91 1
 Näyte 3 kk U-karpu 90 Urine 3 1 3
 T1_Urine_3 First 
204_1 204_1 116 CTATAGTAA CAGCMGCCGCGGTAATWC 79 2
 Näyte 3 kk F-karpu 90 Feces 3 2 1
 T2_Feces_3 Second 
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204_2 204_2 209 ATGTGATTC CAGCMGCCGCGGTAATWC 79 2
 Näyte 3 kk F-karpu 90 Feces 3 2 1
 T2_Feces_3 Second 
32_1 32_1 37 TCGCGTGCT CAGCMGCCGCGGTAATWC 25 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
32_2 32_2 48 AGTGTGCTC CAGCMGCCGCGGTAATWC 25 1
 Näyte 3 kk F-karpu 90 Feces 3 1 3
 T1_Feces_3 First 
33_1 33_1 3 GTATAGTCT CAGCMGCCGCGGTAATWC 26 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
33_2 33_2 57 CGAAGAGCT CAGCMGCCGCGGTAATWC 26 2
 Näyte 12 kk F-karpu 360 Feces 3 2 3
 T2_Feces_12 Second 
42_1 42_1 1 CTATACACT CAGCMGCCGCGGTAATWC 24 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
42_2 42_2 240 CCGCGCACT CAGCMGCCGCGGTAATWC 24 1
 Näyte 12 kk F-karpu 360 Feces 3 1 3
 T1_Feces_12 First 
69_2 69_2 210 GTGTGGCTC CAGCMGCCGCGGTAATWC 48 2
 Näyte 6 kk F-karpu 180 Feces 3 2 3
 T2_Feces_6 Second 
74_1 74_1 147 GTCCTCTCT CAGCMGCCGCGGTAATWC 38 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
74_2 74_2 157 TAGGAGACT CAGCMGCCGCGGTAATWC 38 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
86_1 86_1 201 GCATGATTC CAGCMGCCGCGGTAATWC 65 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
86_2 86_2 34 TCGTATGTC CAGCMGCCGCGGTAATWC 65 2
 Näyte 3 kk F-karpu 90 Feces 4 2 4
 T2_Feces_3 Second 
96_1 96_1 24 ATCTCTCTC CAGCMGCCGCGGTAATWC 55 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
96_2 96_2 50 TTATACATC CAGCMGCCGCGGTAATWC 55 1
 Näyte 12 kk F-karpu 360 Feces 4 1 4
 T1_Feces_12 First 
97_2 97_2 192 CCACATACT CAGCMGCCGCGGTAATWC 62 2
 Näyte 3 kk U-karpu 90 Urine 3 2 3
 T2_Urine_3 Second 
